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ABSTRACT 
Stephen Joseph Capuzzi: Predictive Cheminformatics Analysis of Diverse Chemogenomics 
Data Sources: Applications to drug discovery, assay interference, and text mining. 
(Under the direction of Alexander Tropsha) 
 In this dissertation, we describe the cheminformatics analysis of diverse 
chemogenomics data sources as well as the application of these data to several drug discovery 
efforts. In Chapter 1, we describe the discovery and characterization of novel Ebola virus 
inhibitors through QSAR-based virtual screening. In Chapter 2, we report the discovery and 
analysis of a series of potent and selective doublecortin-like kinase 1 (DCLK1) inhibitors using 
QSAR modeling, virtual screening, Matched Molecular Pair Analysis (MMPA), and molecular 
docking. In Chapter 3, we performed a large-scale analysis of publicly available data in 
PubChem to probe the reliability and applicability of Pan-Assay INterference compoundS 
(PAINS) alerts, a popular computational drug screening tool. In Chapter 4, we explore the 
PubMed database as a novel source of biomedical data and describe the development of 
Chemotext, a publicly available web server capable of text-mining the published literature.  
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CHAPTER 1: COMPUTER-AIDED DISCOVERY AND CHARACTERIZATION OF 
NOVEL EBOLA VIRUS INHIBITORS1 
 
1.2 INTRODUCTION 
The 2014 Ebola outbreak was the largest and most persistent since the discovery of the 
Ebola virus (EBOV) in 1976. Alarmingly, a new EBOV outbreak was confirmed in the Democratic 
Republic of Congo in May 2017.1 Though advances in the research and development of Ebola 
therapeutics have been made,2–4 Ebola drug discovery endeavors are hindered due to the high 
virulence of the EBOV and its biosafety level 4 (BSL-4) classification.5 Recently, a biosafety level 
2 (BSL-2) Ebola virus-like particle (VLP) entry assay was developed and utilized for a drug 
repurposing screen of Food and Drug Administration (FDA)-approved drugs.6–8 The Ebola VLP 
contains glycoprotein (GP) and the matrix protein VP40 fused to a beta-lactamase reporter for 
monitoring of VLP entry into cells. Although this BSL-2 Ebola VLP assay enables rapid 
compound screening, it requires a centrifugation step for assay plates at 1,500 g for 45 minutes at 
4 °C that limits its screening throughput. Computational approaches that leverage generated data 
can be used to design or select small sets of compounds for lead identification in order to reduce 
the time and costs of high throughput screening. Using the existing data from the Ebola VLP entry 
assay as well as cytotoxicity data, QSAR models9 can be built and then employed for virtual 
screening of large chemical libraries to predict activeompounds against EBOV infection with low 
                                                          
1 This chapter previously appeared as an article in the Journal of Medicinal Chemistry. The original citation is as 
follows: Capuzzi, SJ, et. al. “Computer-aided discovery and characterization of novel Ebola virus inhibitors”. Journal 
of Medicinal Chemistry. Just Accepted (April, 2018). 
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expected toxicity. Indeed, QSAR modeling approaches have been previously employed for 
identification of compounds with efficacy against EBOV.10,11 Herein, we describe a study that 
relied on synergistic combination of statistical data modeling and experimental testing for both 
antiviral inhibitor potency and host cell cytotoxicity (Figure 1.1).  Our study utilized both BSL-2 
and BSL-4 assays to experimentally validate hits identified computationally.   
 
Figure 1.1. Overall study design. The present study synergistically incorporates computational 
modeling and experimentation. 
 
To identify compounds with anti-EBOV activity and limited host cell cytotoxicity, we 
designed an integrated QSAR modeling system for virtual compound screening that is combined 
with experimental testing on a focused set of predicted compounds. In this study, existing antiviral 
activity and compound cytotoxicity data were collected and carefully curated; respective QSAR 
models were built and rigorously validated; these models were employed for virtual screening of  
a large chemical library (~17 million compounds), resulting in 102 hits prioritized for experimental 
testing; the anti-EBOV activity in the Ebola VLP assay and cytotoxicity in host cells of these hits 
were determined experimentally in BSL-2 and BSL-4 assays; and the mechanisms of anti-EBOV 
15 
 
 
activity for confirmed hits were identified. Ultimately, 14 potent hits with activity ranging between 
0.272 μM and 9.65 μM as well as more than 10-fold selectivity over compound cytotoxicity in 
host cells were confirmed. Next, five selected hits were shown to inhibit BSL-4 live-EBOV 
infection in a dose-dependent manner. Two of these hits possessed novel scaffolds, making them 
candidates for further medicinal chemistry optimization as potential anti-EBOV agents. This study 
presents the first example of computationally-driven prioritization and experimental discovery of 
novel potent anti-Ebola compounds with high therapeutic windows in the published literature. 
1.3 RESULTS 
1.3.1 Model Performance   
Prior to the modeling, MODIs of 0.69 and 0.68 were calculated for the P1 and P2 datasets, 
respectively. For each protocol, three separate software packages (Chembench, HiT QSAR, and 
GUSAR) employing different descriptors and different machine learning techniques (MLTs) were 
utilized for model building. In total, six individual models were built and rigorously validated. 
Results of 5-fold external cross-validation are presented in Table 1.1. In order to demonstrate that 
the predictive power of the models was not due to random correlation between bioactivity and 
chemical descriptors, 1000 rounds of Y-randomization was performed. No Y-randomized models 
had a CCR above 0.60.   
For P1, models built with HiT QSAR and GUSAR had the highest predictive accuracy, 
irrespective of the use of different chemical descriptors and MLTs. For P2, HiT QSAR again 
showed the best performance. Additionally, the CCR of the Chembench model improved by ~7% 
for P2 over P1. All models were deemed robust and statistically valid (Table 1.1).  
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For HeLa and HEK cell lines, MODI of 0.65 and 0.70 were obtained, respectively. For 
HeLa cytotoxicity, GUSAR yielded the best overall model. Chembench and GUSAR had inverse 
sensitivity and specificity profiles, indicating that Chembench could better identify toxic 
compounds, while GUSAR could better identity non-toxic compound. This observation highlights 
Model Name Descriptors  MLT CCR SE SP PPV NPV 
Chembench – P1 Dragon 6.0 RF 0.67 0.69 0.68 0.66 0.68 
HiT QSAR – P1 SiRMS RF 0.72 0.73 0.71 0.72 0.73 
GUSAR – P1 MNA and QNA SCR-RBF 0.72 0.73 0.71 0.72 0.73 
        
Chembench – P2 Dragon 6.0 RF 0.72 0.72 0.72 0.72 0.72 
HiT QSAR – P2 SiRMS RF 0.75 0.75 0.75 0.75 0.75 
GUSAR – P2 MNA and QNA SCR-RBF 0.72 0.69 0.75 0.73 0.71 
        
Chembench – HeLa Dragon 6.0 RF 0.73 0.77 0.68 0.73 0.72 
HiT QSAR – HeLa SiRMS RF 0.64 0.68 0.60 0.66 0.62 
GUSAR – HeLa MNA and QNA SCR-RBF 0.75 0.67 0.84 0.82 0.69 
        
Chembench – HEK Dragon 6.0 RF 0.62 0.67 0.57 0.64 0.60 
HiT QSAR – HEK SiRMS RF 0.53 0.55 0.50 0.56 0.49 
GUSAR – HEK MNA and QNA SCR-RBF 0.72 0.78 0.71 0.73 0.76 
Table 1.1. Statistical characteristics obtained on 5-fold external CV of all models 
developed in this study. The results with highest statistical metrics are highlighted in bold. 
HEK models built with Chembench and HiT QSAR were not used due to poor predictive 
power. Values below acceptance threshold are underlined. 
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the reciprocal benefit of consensus modeling, i.e., utilizing all the models for VS. No Y-
randomized models had a CCR in access of 0.60.  All models were deemed robust and statistically 
valid. For HEK cytotoxicity, GUSAR again proved to be the best overall model. On the other hand, 
Chembench and HiT QSAR were not statistically validated, as several metrics fell below the 0.60 
threshold. Thus, only GUSAR was used for prediction of HEK cytotoxicity. Y-randomized models 
for GUSAR did not exceeded a CCR of 0.60.  A summary of all model performance can be found 
in Table 1.1.  
1.3.2 QSAR-Based Virtual Screening 
QSAR-based virtual screening (VS) was carried out according to the workflow presented 
in Figure 1.2. Initially, ~17 million compounds (see Methods) were downloaded, prepared, and 
screened. As previously stated, “hits” were those compounds that were within the AD of the 
respective model and predicted by all models to have high antiviral activity and limited host 
cytotoxicity. In total, 102 VS hits were selected for experimental validation in the Ebola-VLP entry 
assay.  
  
Figure 1.2. Screening workflow. A virtual chemical library of ~17 million compounds was 
screened against a battery of antiviral (P1 and P2) and cytotoxicity (HEK and HeLa) models. Hits 
selected for experimental validation were predicted to be EBOV inhibitors with limited host 
cytotoxicity. Then computational hits were experimentally validated, then their activity was 
evaluated using percent inhibition, IC50 values, and selectivity index (SI). 
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1.3.3 Experimental Evaluation 
1.3.3.a Experimental confirmation of Anti-EBOV activity of 14 compounds 
Based on the virtual screening results, 102 compounds were purchased and experimentally 
screened in the Ebola-VLP entry assay in parallel with an ATP content assay to determine 
compound cytotoxicity in host cells. All compounds were screened at 11 concentration dilutions 
ranging from 0.001 to 57 µM.12 Out of 102 compounds tested, 51 showed greater than 50% 
inhibition, indicating that half of compounds had confirmed anti-EBOV activity. Next, 20 of these 
51 compounds exhibited the IC50 values under 10 μM. Because the compound cytotoxicity at 
higher compound concentrations might reduce the Ebola VLP entry in cells, these potential false 
positive compounds should be deprioritized. After comparing to the compound cytotoxicity data, 
14 of these confirmed compounds showed a greater than 10-fold selectivity index (SI) of anti-
Ebola VLP entry over compound cytotoxicity. Vindesine and BIX-01294 inhibited the virus in the 
nanomolar range (Figure 1.3).  
 
Figure 1.3. Dose response curves for vindesine and BIX-01294. Both antiviral (VLP 
entry) and host cell cytotoxicity (HeLa) activities are plotted. 
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Moreover, these 14 confirmed compounds, except for ZINC91973695 and ZINC67869167, have 
known mechanisms of action (MOAs) and therapeutic indications (Table 1.2), including eight 
anti-cancer, two antihistamines, and two anti-psychotic and anti-inflammatory agents (Table 1.2).  
Table 1.2. Experimental results for the top 14 hits. Most experimentally confirmed hits have 
known MOAs and therapeutic use indications. 
Name Potency, μM 
Selectivity 
Index 
Indication MOA 
Vindesine 0.272 1837 Anticancer Microtubule Inhibitor 
BIX-01294 0.966 45 Anticancer HMTase Inhibitor 
Afimoxifene 1.96 123 Anticancer 
Estrogen Receptor 
Modulator 
Tetrandrine 2.16 22 
Anti-
inflammation 
Calcium Channel Blocker 
NVP-ADW742 3.05 13 Anticancer Tyrosine Kinase Inhibitor 
Endoxifen 3.05 164 Anticancer 
Estrogen Receptor 
Modulator 
ZINC91973695 6.09 82 N/A N/A 
Deptropine 6.58 76 Antihistamine Anticholinergic 
GANT61 6.83 73 Anticancer Hedgehog Antagonist 
20 
 
 
 
The remaining two compounds obtained from the ZINC database (ZINC91973695 and 
ZINC67869167) have no previously reported bioactivities, anti-Ebola or otherwise. Five hits were 
further validated in a live EBOV infection assay at bio-safety level-4 (BSL-4). All five hits showed 
dose-response inhibition against EBOV infection (Figure 1.4). Vindesine was the most potent 
compounds with an IC50 of 0.34 µM. The IC50 values of NVP-ADW742, BIX-01294, 
ZINC67869167, and ZINC91973695 were between 1 µM to 10 µM in the live EBOV infection 
assays.  
ZINC67869167 6.83 73 N/A N/A 
Hh-Ag1.5 7.67 65 Anticancer Hedgehog Agonist 
Cediranib 7.67 65 Anticancer Tyrosine Kinase Inhibitor 
Ebastine 9.56 51 Antihistamine Histamine H1 Antagonist 
Osanetant 9.65 52 Antipsychotic 
Neurokinin 3 Receptor 
Antagonist 
21 
 
 
 
Figure 1.4. Dose-response behavior against BSL-4 live-EBOV infection. Five hits were 
selected for screening in live-EBOV infection in a BSL-4 assay. Vindesine (red) was the most 
potent compounds with an IC50 of 0.34 µM. The IC50 values of NVP-ADW742 (black), BIX-
01294 (green), ZINC67869167 (orange), and ZINC91973695 (blue) were between 1 µM to 10 
µM.   
 
1.3.3.b Mechanisms of action against EBOV entry 
We probed the chemical biology of these hit compounds in both viral and host systems in 
order to uncover the mechanisms of anti-EBOV action. We examined the potential sites for drug 
interaction including Niemann Pick C1 (NPC1) protein, lysosomal function, cathepsin B, and 
cathepsin L,13–15 as well as the direct binding of these compounds to the Ebola VLP proteins using 
thermal shift binding assays.16 The results of chemical biology studies revealed that these 
compounds may act via one or more these targets/mechanisms. 
The process of EBOV entry into cells involves binding of viral envelop protein(s) to the 
cell membrane receptor protein/molecule, endocytosis, movement of endocytic vesicles to 
early/late endosomes and lysosomes, and ejection of viral RNA into the cytosol.17 Therefore, 
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inhibition of viral protein binding to cell membrane proteins/binding partners can effectively 
reduce viral entry and subsequent viral replication in cells. Because the cell surface binding 
protein/molecule for Ebola viral proteins is still unclear, we determined direct binding of these 
compounds to recombinant Ebola protein. To examine whether these compounds directly interact 
with the EBOV, their ability of stabilizing Ebola protein was tested in a thermal shift assay using 
recombinant Ebola VLP. None of the compounds at 50 μM were able to protect Ebola VLP from 
thermal denaturation. (Figure 1.5). 
 
 
Figure 1.5. Thermal profiling results of Ebola VLP with Ebola entry inhibitors. A, 
Thermal stability of Ebola VLP at temperatures from 25 °C to 77 °C detected by western 
blot. B, Effects of Ebola entry inhibitors (GANT61, ZINC67869167, ZINC91973695, 
tetrandrine, deptropine, osanetant, BIX-01294, cediranib, ebastine, afimoxifene, NVP-
ADW742, vindesine, endoxifen, Hh-Ag1.5) on thermal stability of Ebola VLP at 62 °C. All 
experiments were performed in duplicate and data are representative of two independent 
experiments. 
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Cathepsin B and L are lysosomal endopeptidases that had been reported to prime EBOV 
proteins in lysosomes before the viral RNAs are injected into the cytosol for virus replication. 
Inhibition of cathepsin B or L significantly reduces EBOV infection.13 GANT61 (an inhibitor of 
GLI1 and GLI2-induced transcription), deptropine (an antihistamine), and ebastine (an 
antihistamine) inhibited the enzymatic activity of cathepsin L (Figure 1.6a and 1.6b). Only 
GANT61 inhibited enzymatic activity of cathepsin B (Figure 1.6c and 1.6d). 
  
Figure 1.6. Inhibition of protease activities of recombinant cathepsin L and cathepsin B by 
Ebola entry inhibitors. a and b. recombinant cathepsin B or cathepsin L were treated with 10 µM 
of GANT61, ZINC67869167, ZINC91973695, tetrandrine, deptropine, osanetant, BIX-01294, 
cediranib, and ebastine. c. Dose-response studies of GANT61, deptropine and ebastine in cathepsin 
24 
 
 
L assay. d. Dose-response studies of GANT61 in cathepsin B assay. All experiments were 
performed in triplicate and data are representative of at least two independent experiments. Data 
are represented as mean ± SEM. 
 
The NPC1 protein has been reported as an intracellular receptor for EBOV.14,15,18 
Significant reduction of EBOV entry and infection were observed in the NPC1-deficient cells and 
mouse models.14,19 Ebastine increased cholesterol accumulation in cells determined by the filipin 
staining assay, which indicated a functional impairment of NPC1 protein; whereas, the other eight 
evaluated hits did not impair NPC1 protein function (Figure 1.7a).  
Lysosomes in cells are enlarged after treatment with certain compounds that damage 
lysosome functions, resulting in accumulation of lipids and other macromolecules.20 The enlarged 
lysosomes are often observed in the patient cells with lysosomal storage diseases caused by 
mutations in lysosomal proteins and lipid accumulation.21 EBOV entry is significantly reduced 
after the lysosomal functions are impaired by compounds. All of the nine evaluated hits increased 
LysoTracker dye staining in cells, indicating an enlargement in lysosome size (Figure 1.7b).  
25 
 
 
  
Figure 1.7. Cholesterol accumulation (NPC1 inhibition) and enlargement of lysosome 
induced by Ebola entry inhibitors. a. U18666A and ebastine increased filipin staining in 
fibroblasts (green: filipin; blue: nuclei). b. U1866A, GANT61, ZINC67869167, ZINC91973695, 
tetrandrine, deptropine, osanetant, BIX-01294, cediranib, and ebastine increased LysoTracker 
staining in fibroblasts (orange: LysoTracker red; blue: nuclei). All experiments were performed in 
triplicate and data are representative of at least two independent experiments. Data are represented 
as mean ± SEM. 
 
1.3.4 Cheminformatics Analysis 
1.3.4.a Assay Liabilities 
First, using substructural pattern matchers implemented in ZINC15,22 the 14 
experimentally confirmed hits were found to be free of chemical aggregation liabilities23 and 
PAINS alerts24. Since the assay employed herein relied on a beta-lactamase reporter system, all 14 
hits were also checked for potential beta-lactamase inhibition trends using PubChem 
26 
 
 
* 
Promiscuity.25 No heightened beta-lactamase assay activity trends were observed, indicating that 
these hits are not assay artifacts (Supplementary File 14).  
1.3.4.b Chemical Similarity to Training Set Compounds 
Hierarchical clustering analysis revealed that majority of the hits are structurally dissimilar 
from each other, aside from afimoxifene and endoxifen (Figure 1.8).  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.8. Hierarchical clustering 
of experimental hits. High 
Tanimoto similarity of afimoxifene 
and endoxifen is highlighted by an 
asterisk.  
Low High 
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Clustering thus indicates the hits discovered in this study access a wide range of chemical 
space across several unique chemotypes. The structural similarity based on the Tanimoto 
coefficient (Tc) of the 14 hits were then compared with compounds in the antiviral training sets 
(Table 1.3) in order to assess the uniqueness of hits. In addition to being highly structurally similar 
to each other, afimoxifene and endoxifen both have Tc above 0.90 to tamoxifen, which was a 
previously reported anti-Ebola inhibitor.26 Likewise, tetrandrine is highly structurally similar 
(Tc=0.97) to cepharanthine, a training set active compound.  The most potent hit in this study, 
vindesine, had a Tc of 0.96 to vinblastine, which was the most potent hit in the original screen.26 
These hits, while not entirely unique from a chemical perspective, illustrate that the developed 
QSAR models are robust and that the experimental assays are reproducible. The remaining 10 hits 
were considerably dissimilar from any training set compounds (Tc = 0.63-0.89), thereby 
constituting novel anti-Ebola chemotypes as compared to the training set compounds.   
 1.3.4.c Comparison to Previously Reported EBOV Inhibitors 
The potencies  and structures of the 14 hits identified in this study were compared to a 
compiled set of 60 previously published compounds with either in vitro or in vivo anti-Ebola 
activity.2,7,27,28 The full list of previously known published compounds and their potencies can be 
found in the Supplementary File 15. 
The most potent hit identified from virtual screen was vindesine (0.272 μM), a vinca 
alkaloid microtubule inhibitor. Previously, other vinca alkaloids were reported as sub-micromolar 
inhibitors of the EBOV in vitro.  These vinca alkaloids, vinblastine (0.048 μM), vinorelbine (0.066 
μM), and vincristine (0.141 μM),7 are highly structurally similar to vindesine (Table 1.4). 
Colchicine and nocodazole, microtubule inhibitors that are structurally distinct from the vinca 
alkaloids, were also previously reported as sub-micromolar inhibitors. The identification of 
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vindesine as one of the most potent hits identified to date highlights the robustness of the developed 
QSAR models, as well as the efficacy of this class of compounds and compounds with the same 
associated MOA as viable anti-Ebola compounds.  
The second most potent hit identified from the virtual screen was BIX-01294 (0.97 μM).  
This compound is among most potent reported anti-Ebola compounds.  Moreover, BIX-01294 is 
structurally dissimilar from other previously reported compounds (Table 1.4) and has a unique 
primary MOA (G9a histone methyltransferase inhibition).29 In contrast to vindesine, the 
identification of BIX-01294 demonstrates the ability to QSAR-based virtual screening to retrieve 
structurally novel chemotypes. 
The next most potent series of hits includes afimoxifene (1.36 μM), tetrandrine (2.16 μM), 
NVP-ADW742 (3.05 μM), and endoxifen (3.05 μM). Afimoxifene and endoxifen are metabolites 
of tamoxifen (Table 1.4), which was previously reported as a sub-micromolar Ebola inhibitor 7. 
Likewise, tetrandrine is structurally similar to cepharanthine (Table 1.4),7 as both are isolated from 
the same plant genus.  NVP-ADW742, on the other hand, is structurally dissimilar from any 
previously reported compound (Table 1.4). However, additional tyrosine kinase inhibitors have 
shown efficacy against the EBOV with a range of potencies in vitro, such as sunitinib (1.91 μM) 
and nilotinib (24.3 μM).7 
The remaining hits, i.e., ZINC91973695, deptropine, GANT 61, ZINC67869167, Hh-
Ag1.5, cediranib, ebastine, osanetant, have potencies ranging from 6.09 μM – 9.65 μM (Table 
1.4). Each of these hits is structurally unique with respect to previously published compounds 
(Table 1.4). In addition to being structurally novel among EBOV inhibitors, ZINC91973695 and 
ZINC67869167 have no previously reported bioactivities.   
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Table 1.3. Structural similarity of top hits to previously published compounds. The Tanimoto 
coefficient (TC) between experimentally confirmed hits and compounds in the literature was 
calculated. 
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1.4 DISCUSSION 
The power of virtual screening is its ability to quickly process millions of compounds and 
prioritize a small set of highly confident predictions for experimental confirmation. This approach 
not only saves time and cost as compared to the experimental high throughput screening, but also 
may lead to the evaluation of additional approved drugs that could be missed in the physical 
compound screening library. A combination of virtual screening with experimental confirmation 
is especially useful for challenging assays due to high biosafety requirements, limited patient 
samples, expensive reagents, or difficult formats (small animal or 3D cell culture). In this study, 
we prioritized 102 compounds from an in silico library of ~17 million compounds for testing in 
the EBOV entry assay using QSAR modeling and virtual screening. Fourteen of these hits were 
experimentally confirmed, including 5 selected hits against live-EBOV infections, and their anti-
Ebola mechanisms of action were determined using. 
The EBOV entry process has been extensively studied. Viral envelope glycoproteins attach 
to the surface of host cell, and the virus enters through micropinocytosis and endocytosis. Although 
a cell surface receptor and a few other components are still not clear, several key host factors 
including cathepsin B/L in the endosome13 and Niemann Pick C1 protein (NPC1) in the lysosome 
have been reported as regulators of EBOV entry.14,15 The chemical biology and anti-Ebola MOAs 
of the 14 experimentally validated hits were evaluated for interactions with both host and viral 
targets.  
In addition to discovering compounds with unique scaffolds, we also uncovered the anti-
Ebola MOAs of these compounds. We have found that the antihistamines ebastine and deptropine 
inhibited Ebola entry through negatively regulated lysosome function and blocking cathepsin L 
35 
 
 
activity. We also found that osanetant, an anti-psychotic, induces the enlargement of lysosomes 
and impairs lysosomal function. Additionally, BIX-01294 showed sub-micromolar activity to 
inhibit EBOV entry. Our LysoTracker dye staining data indicated that BIX-01294 may block 
EBOV entry through a blockade of lysosome function in host cells. BIX-01294 is a G9a histone 
methyltransferase (HMTase) inhibitor.29 HMTases have not been implicated in EBOV entry or 
replication. Additional chemical biology experiments to test the importance of HMTases in EBOV 
entry should be performed. Two hedgehog-signaling pathway modulators, Hh-Ag1.5 and 
GANT61,30 showed moderate anti-Ebola activity. Our results revealed multiple mechanisms of 
action involved in the inhibition of EBOV entry by GANT61. GANT61 caused enlargement of 
lysosomes and inhibited both cathepsin L and cathepsin B, which are known to impair EBOV 
entry. Two hits from the QSAR-based screen, ZINC91973695 and ZINC67869167, have no 
previously reported bioactivities. Results of our chemical biology evaluations showed that both 
compounds induced enlargement of lysosomes, which may implicate the blockage of lysosomal 
function as a mechanism of action for these two compounds with novel anti-Ebola scaffolds. 
A few analogs of previously reported Ebola entry inhibitors or compounds with the same 
of mechanisms of action were also identified. The most potent hit from our screen (and one of the 
most potent reported EBOV inhibitors) was vindesine, a vinca alkaloid microtubule inhibitor. 
Indeed, the vinca alkaloid microtubule inhibitors vinblastine, vincristine, and vinorelbine were also 
potent hits in the original screen.26 Likewise, though afimoxifene and endoxifen are novel hits, 
Selective Estrogen Receptor Modulators (SERMs) have been shown in several studies to have 
anti-Ebola activity.26,31,32 The same is true for the receptor tyrosine kinase (RTK) inhibitors 
cediranib and NVP-ADW742, as sunitinib has been previously reported to have anti-Ebola 
activity.26 Last, tetrandrine, a calcium-ion channel blocker, was reported33 as potent anti-Ebola 
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inhibitor during the course of our study. Thus, these results demonstrate the ability of our QSAR 
models to reliably retrieve compounds with anti-Ebola activities and confirm the reproducibility 
of the VLP-assay.  
1.5 CONCLUSIONS 
Our study is the first case of QSAR-driven experimental discovery of novel anti-Ebola 
agents with limited host cell toxicity. Robust and predictive QSAR models for both anti-Ebola 
activity and host cytotoxicity were developed and used for virtual screening of ~17 million 
compounds in order to identify Ebola inhibitors with high therapeutic windows (selectivity 
indices). Ultimately, 102 VS hits were tested in both Ebola VLP and ATP content cytotoxicity 
assays; 14 of these hits had IC50 < 10 μM and SI > 10, which is comparable to the measured 
potencies of several previously reported compounds. The two most potent hits in the screen were 
vindesine, a vinca alkaloid microtubule inhibitor, and BIX-01294, an HMTase inhibitor (Table 
1.2). In a live-EBOV assay, vindesine had an IC50 of 0.34 µM. Several of the hits were SERMs 
and RTKs, which have MOAs known to be related to anti-Ebola activity. We investigated the 
previously uncharacterized MOAs for anti-Ebola activity of several hits, including both host 
factors and direct Ebola VLP interactions. Two compounds, ZINC91973695 and ZINC67869167, 
represent novel chemotypes and can be considered as leads for future anti-Ebola chemical 
optimization.  
In addition to the identification of these compounds, this study demonstrates that FDA-
approved drugs, such as vindesine, and compounds that have not yet passed clinical trials for their 
primary indications, like cediranib, can be repurposed as antivirals. Such compounds are of 
particular interest, as they may have the potential, pending additional pre-clinical evaluation, to be 
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granted orphan drug status in the United States for EBOV disease. The integrated computational 
and experimental strategy employed in this study represents an advancement for the rapid 
discovery of Ebola therapeutics.  
1.6 EXPERIMENTAL SECTION 
1.6.1 Data Collection, Curation, and Classification  
1.6.1.a Antiviral Data 
Prior to this work, the Ebola VLP was prepared at the Icahn School of Medicine at Mount 
Sinai, and VLP-based qHTS screening campaigns were performed at the National Center for 
Advancing Translational Sciences (NCATS) at the National Institutes of Health (NIH).26 The 
results of 4 qHTS screening campaigns (2 primary and 2 confirmatory) were extracted from 
PubChem (AIDs 1117318, 1117313, 1117312, and 1117308).34,35 These data are available in 
Supplementary Files 1-4.   
Each of the four screens has three readouts, including a blue, green, and ratio (blue/green) 
channel. The blue channel analyzes the efficacy of the compound at inhibiting VLP entry activity 
in the host cell. The green channel indicates the healthy and viable cells that loaded with CCF2-
AM. The ratio channel screen measures the ratio of blue/green spectra. The beta-lactamase in the 
VLP hydrolyzes the CCF2-AM dye used in the assay to give a blue fluorescence spectrum. An 
effective inhibitor will prohibit the beta-lactamase in the VLP from hydrolyzing CCF2-AM, 
resulting in reduction of the intensity of the blue fluorescence spectrum. A low blue emission 
spectrum indicates that the compound is inhibitory, while a high green emission spectrum reflects 
the absence of host cytotoxicity. A simplified schema of the assay is depicted in Figure 1.9. 
In total, 3121 compounds were tested. These data were then curated according to our well-
established protocols.36–38 Briefly, mixtures, inorganics, and organometallics were removed. 
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Additionally, replicate compounds were identified and sets were removed if screening results 
conflicted; if the results were concordant, then one representative compound was selected. After 
curation, 3104 unique compounds remained.   
  
Figure 1.9. Simplified schema of Ebola VLP assay. Ebola VLPs contain Ebola GP and the VP40 
protein fused to a beta-lactamase (Bla) reporter. HeLa cells are loaded with the beta-lactamase 
substrate CCF2-AM. If the VLP enters into the cell, Bla hydrolyzes the substrate CCF2-AM, 
disrupting the fluorescence resonance energy transfer (FRET) in the substrate, thus causing blue 
fluorescence. Inhibition of the VLP by a chemical will preserve the substrate FRET, maintaining 
a green fluorescence. The ratio of blue/green fluorescence intensities represents the VLP activity 
of inside cells. 
 
1.6.1.b Cytotoxicity Data 
Host cell cytotoxicity data for a subset of compounds tested for anti-EBOV activity were 
obtained from the researchers at the NCATS. Compounds were tested for host cytotoxicity 
potential in HeLa and HEK cell lines. In total, 171 unique compounds were tested in HeLa cell 
39 
 
 
line, and 156 unique compounds were tested in HEK cell line. All 156 compounds tested in the 
HEK cell line were also tested in the HeLa cell line. Data curation was performed as above, and 
one organometallic was removed, leaving 170 and 155 compounds for consideration from the 
HeLa and HEK cell lines, respectively.  These data are available in Supplementary Files 5-6. 
1.6.1.c Determination of Antiviral Activity 
  Only compounds with dose-response curve classes39 of 1.1, 1.2, 2.1, 2.2, and 4 were 
considered for potential inclusion into the QSAR model training set. In order to comprehensively 
characterize the results of the screens, two separate protocols were used to classify “active” and 
“inactive” compounds for subsequent QSAR modeling. In the first protocol (P1), a compound was 
classified as “active” if and only if the compound had an AC50 < 10 μM and Maximum Inhibition 
≥ 70% in both a primary and confirmatory screen.  Similarly, an “inactive” compound had an AC50 
≥ 10 μM and Maximum Inhibition < 70% in both a primary and confirmatory screen.  
In the second protocol (P2), an “activity” score was calculated for each compound, j, according to 
the following equation  
 
where activity score(j) is the relative activity of a specific compound; max(AC50) and min(AC50) 
are the maximum and minimum AC50 in the screen, respectively, and AC50(j) is the AC50 of a 
specific compound; max(efficacy) and min(efficacy) are the maximum and minimum efficacies in 
the screen, respectively, and efficacy(j) is the efficacy of a specific compound. If a compound had 
an activity score ≥ 70 in either primary or confirmatory screen, the compound was classified as 
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“active”. Similarly, if a compound had an activity score < 70 in either a primary or confirmatory 
screen, the compound was classified as “inactive”.  
1.6.1.d Determination of Cytotoxicity  
For both the HeLa and HEK cell lines, a compound was considered “toxic” if the associated 
pAC50 > 4.0 (AC50 < 100 μM); whereas, a compound was considered “non-toxic” if the pAC50 ≤ 
4.0 (AC50 ≥ 100 μM) or the curve class was 4, indicating no response. Only compounds with dose-
response curve classes39 of 1.1, 1.2, 2.1, 2.2, and 4 were considered.   
1.6.1.e Antiviral Training Set Balancing  
In both protocols (P1 and P2), the data were imbalanced towards the inactive class. Thus, 
in order to balance the active and inactive classes in a 1:1 ratio, the inactive class was down-
sampled.40 Fifty percent of the corresponding inactives with the highest Tanimoto similarity41, i.e., 
the most similar inactives to the compounds from active class based on MACCS keys fingerprint,42 
were chosen, and the remaining 50% of the corresponding inactives were randomly selected. 
Important to note that all rationally chosen inactives had different nearest neighbors among 
actives.43  For P1 and P2, a total of 166 compounds (83 active and 83 inactive) and 1224 
compounds (612 active and 612 inactive) formed the respective training sets.  These compounds 
are available in Supplementary Files 7-8. 
1.6.1.f Cytotoxicity Training Set Balancing  
The “toxic” and “non-toxic” classes were relatively balanced; thus, no down-sampling of 
the larger class was required.  For HeLa and HEK cell lines, a total of 170 compounds (90 toxic 
and 80 non-toxic) and 155 compounds (83 toxic and 72 non-toxic) formed the respective training 
sets. These compounds are available in Supplementary Files 9-10. 
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1.6.1.g Modelability Index (MODI)   
The MODelability Index (MODI) estimates the likelihood of obtaining predictive QSAR 
models for a binary data set of compounds.44 MODI is defined as a weighted ratio of the number 
of nearest-neighbor pairs of compounds in descriptor space with the same activity class versus the 
total number of pairs. MODI threshold of 0.65 was previously found to separate the modelable 
from non-modelable data sets.44 MODI was calculated for all antiviral and cytotoxicity datasets 
prior to QSAR modeling in the present study as described earlier.44   
1.6.2 Computational Methods 
1.6.2.a QSAR Model Generation and Validation  
Three separate packages, Chembench,45,46 HiT QSAR,47 and GUSAR,48 were employed 
for consensus classification modeling of both antiviral activity (P1 and P2) and host cytotoxicity 
(HeLa and HEK). QSAR models built on Chembench used Dragon 6.0 descriptors49 and the 
random forest50 machine-learning algorithm. For models built with HiT QSAR, Simplex 
Representation of Molecular Structure (SiRMS) descriptors51 and random forest (RF) were used.  
GUSAR models utilized a combination of Multilevel Neighborhoods of Atoms (MNA) and 
Quantitative Neighborhoods of Atoms (QNA) descriptors52 and a radial-basis function with self-
consistent regression (RBF-SCR) as the machine-learning algorithm.48 We have followed best 
practices of QSAR modeling developed earlier by our group. All models were rigorously validated 
using five-fold external cross validation.9 Y-randomization was performed for all models.9 Models 
were statistically evaluated according to, sensitivity (SE), specificity (SP), correct classification 
rate (CCR), positive predictive value (PPV), and negative predictive value (NPV).  These 
statistical metrics are calculated by the equations 1-5, respectively.   
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SE =  
TP
TP+FN
   (1) 
SP =  
TN
TN+FP
  (2) 
CCR =  
SE+SP
2
  (3) 
PPV =  
TP
TP+FP
  (4) 
NPV =  
TN
TN+FN
  (5) 
Here, TP and TN represent the number of true positives (correct classifications of actives), and 
true negatives (correct classifications of inactives), respectively; whereas, FP and FN represent the 
number of false positives (incorrect classifications of actives) and false negatives (incorrect 
classifications of inactives), respectively. 
1.6.2.b Virtual Screening  
Two in silico libraries, the ZINC drug-like library22 and previously untested drugs and 
experimental compounds from the NCATS Chemical Genomics Center Pharmaceutical Collection 
(NPC), totaling ~17 million compounds after curation (see above), were virtually screened using 
the developed QSAR models of antiviral activity and host cytotoxicity. A model was deemed 
acceptable for virtual screening if and only if the CCR, SE, SP, PPV, and NPV were all above 
0.60, and no associated Y-randomized model had a CCR above 0.60. An applicability domain 
(AD) was used for all models. Consensus prediction was utilized, meaning that for a compound to 
be considered a virtual screening “hit”, it must be within the AD of each model and be predicted 
as “active” and “non-toxic” in all developed QSAR models of antiviral activity and host 
cytotoxicity, respectively (Figure 1.2). Once virtual screening “hits” were experimentally 
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validated, the Sequential Agglomerative Hierarchical Nonoverlapping (SAHN) method 
implemented in the ISIDA/Cluster program53 was used to probe the uniqueness of hit chemotypes 
and to identify the most structurally similar compounds in the training set and in the published 
literature.   
1.6.3 Experimental Methods 
Ebola VLPs containing a beta-lactamase-fused VP40 and GP were prepared in Dr. García-
Sastre's lab, as previously described.6 LiveBLAzer FRET–B/G Loading Kit and CCF2-AM, 
Dulbecco's modified Eagle's medium (DMEM), and Opti-MEM reduced serum medium were 
purchased from Life Technologies (Carlsbad, CA, USA). An ATP content cell viability assay kit 
was purchased from Promega (Madison, WI, USA). 1536-well polystyrene plates were purchased 
from Greiner Bio-One (Monroe, NC, USA). Compounds were purchased from Sigma-Aldrich (St. 
Louis, MO, USA), Santa Cruz (Dallas, TX, USA), ChemBridge Corporation (San Diego, CA, 
USA), Enamine Ltd (Kiev, Ukraine), Maybridge Chemical Company (Altrincham, United 
Kingdom), Vitas-M Laboratory (Champaign, IL, USA), Ambinter (Orléans, France) and AKos 
Consulting & Solutions Deutschland GmbH (Steinen-Schlächtenhaus, Germany) at the highest 
available purity. All of the compounds were dissolved as a 10 mM stock solution in dimethyl 
sulfoxide (DMSO) and diluted in DMSO at a 1∶3 dilution to generate eleven concentrations in 384-
well plates, followed by reformatting into one 1536-well compound plate for high throughput 
screening. 
1.6.3.a Materials  
All commercially available reagents, compounds, and solvents were purchased and used 
without further purification. Column chromatography on silica gel was performed on RediSep 
column using the Teledyne Isco CombiFlash Rf system. Preparative purification was performed 
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on a Waters semi-preparative HPLC. The column used was a Phenomenex Luna C18 (5 micron, 
30 × 75 mm) at a flow rate of 45 mL/min. The mobile phase consisted of acetonitrile and water 
(each containing 0.1% trifluoroacetic acid). A gradient of 10% to 50% acetonitrile over 8 
minutes was used during the purification. Fraction collection was triggered by UV detection (220 
nm).  
1H spectra were recorded using an INOVA 400 MHz spectrometer (Varian).  Samples were 
analyzed on an Agilent 1200 series LC/MS using a Zorbax Eclipse XDB-C18 reverse phase (5 
micron, 4.6 x 150 mm) column and a flow rate of 1.1 mL/min. The mobile phase was a mixture of 
acetonitrile and H2O each containing 0.05% trifluoroacetic acid. LC Method A: a gradient of 4% 
to 100% acetonitrile over 7 minutes was used during analytical analysis. LC Method B: a gradient 
of 4% to 100% acetonitrile over 3 minutes was used during analytical analysis. High resolution 
mass spectrometry was recorded on Agilent 6210 Time-of-Flight LC/MS system.  
2,2'-((2-(pyridin-4-yl)dihydropyrimidine-1,3(2H,4H)-diyl)bis(methylene))bis(N,N-
dimethylaniline) (GANT61) 
 
 
1H NMR (400 MHz, DMSO-d6) δ 8.59 – 8.52 (m, 2H), 7.70 – 7.64 (m, 2H), 7.47 (dd, J = 7.6, 
1.7 Hz, 2H), 7.20 – 7.11 (m, 2H), 7.08 – 6.97 (m, 4H), 4.01 (s, 1H), 3.51 (d, J = 14.1 Hz, 2H), 
3.39 (d, J = 14.2 Hz, 2H), 2.81 (dt, J = 11.2, 4.1 Hz, 2H), 2.50 (s, 12H), 2.22 – 2.14 (m, 2H), 
1.62 – 1.55 (m, 2H). LC/MS (Method B): (electrospray +ve), m/z 430.3 (MH)+, tR = 3.826, UV254 
> 98%. 
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(1R,3R,5S)-3-((10,11-dihydro-5H-dibenzo[a,d][7]annulen-5-yl)oxy)-8-methyl-8-
azabicyclo[3.2.1]octane 2-hydroxypropane-1,2,3-tricarboxylate (Deptropine citrate) 
 
 
HRMS calculated for : C23H28NO [M + H]
+ 334.2165, found 334.2150. LC/MS (Method A): 
(electrospray +ve), m/z 334.1 (MH)+, tR = 5.000, UV254 > 98%. 
 
(11S,31S)-16,36,37,54-tetramethoxy-12,32-dimethyl-11,12,13,14,31,32,33,34-octahydro-2,6-
dioxa-1(7,1),3(8,1)-diisoquinolina-5(1,3),7(1,4)-dibenzenacyclooctaphane (Tetrandrine) 
 
 
1H NMR (400 MHz, DMSO-d6) δ 7.45 (dd, J = 8.2, 2.1 Hz, 1H), 7.08 (dd, J = 8.2, 2.5 Hz, 1H), 
6.91 (d, J = 8.2 Hz, 1H), 6.77 (dd, J = 8.2, 1.9 Hz, 1H), 6.71 – 6.59 (m, 2H), 6.42 – 6.34 (m, 2H), 
6.31 (dd, J = 8.3, 2.1 Hz, 1H), 5.92 (s, 1H), 3.89 (dd, J = 10.4, 5.9 Hz, 1H), 3.80 (s, 3H), 3.68 (s, 
3H), 3.50 (d, J = 9.8 Hz, 1H), 3.41 (d, J = 4.7 Hz, 1H), 3.32 (s, 3H), 3.29 (s, 4H), 3.17 (dd, J = 
12.5, 5.9 Hz, 1H), 3.03 (s, 3H), 2.89 – 2.68 (m, 6H), 2.63 (dd, J = 13.6, 10.1 Hz, 1H), 2.36 (d, J 
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= 16.0 Hz, 1H), 2.28 (d, J = 13.5 Hz, 1H), 2.18 (s, 3H). HRMS calculated for C38H44N2O6 [M + 
2H]2+ 312.1594, found 312.1602. LC/MS (Method A): (electrospray +ve), m/z 623.2 (MH)+, tR = 
3.866, UV254 > 98%. 
 
 
 
(Z)-4-(1-(4-(2-(dimethylamino)ethoxy)phenyl)-2-phenylbut-1-en-1-yl)phenol (Afimoxifene) 
 
 
1H NMR (400 MHz, DMSO-d6) δ 9.40 (s, 1H), 7.22 – 7.13 (m, 2H), 7.09 (ddd, J = 6.8, 4.0, 1.3 
Hz, 4H), 7.01 – 6.94 (m, 2H), 6.78 – 6.72 (m, 2H), 6.72 – 6.66 (m, 2H), 6.61 – 6.54 (m, 2H), 
3.88 (t, J = 5.9 Hz, 2H), 2.52 (m, 2H), 2.40 (d, J = 7.3 Hz, 2H), 2.15 (s, 5H), 0.84 (t, J = 7.4 Hz, 
3H). HRMS calculated for C26H30NO2 [M + H]
+ 388.2271, found 388.2288. LC/MS (Method A): 
(electrospray +ve), m/z 388.1 (MH)+, tR = 5.056, UV254 > 98%. 
 
4-(4-(benzhydryloxy)piperidin-1-yl)-1-(4-(tert-butyl)phenyl)butan-1-one (Ebastine) 
 
 
HRMS calculated for C32H40NO2 [M + H]
+ 470.3054, found 470.3069. LC/MS (Method A): 
(electrospray +ve), m/z 470.2 (MH)+, tR = 6.088, UV254 > 98%. 
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methyl (3S,5S,7S,9S)-9-((3aR,3a1R,4R,5S,5aR,10bR)-5-carbamoyl-3a-ethyl-4,5-dihydroxy-
8-methoxy-6-methyl-3a,3a1,4,5,5a,6,11,12-octahydro-1H-indolizino[8,1-cd]carbazol-9-yl)-5-
ethyl-5-hydroxy-1,4,5,6,7,8,9,10-octahydro-2H-3,7-methano[1]azacycloundecino[5,4-
b]indole-9-carboxylate sulfate (Vindesine) 
 
 
1H NMR (400 MHz, DMSO-d6) δ 9.67 (s, 1H), 7.52 (d, J = 7.9 Hz, 1H), 7.34 (d, J = 8.1 Hz, 1H), 
7.26 (s, 1H), 7.17 (d, J = 3.1 Hz, 1H), 7.08 (t, J = 7.5 Hz, 1H), 7.00 (t, J = 7.5 Hz, 1H), 6.43 (s, 
1H), 6.25 (s, 1H), 5.72 (dd, J = 10.7, 4.8 Hz, 1H), 5.61 (d, J = 10.6 Hz, 1H), 5.07 (s, 1H), 4.34 (s, 
1H), 3.75 (s, 5H), 3.58 (s, 3H), 3.45 (s, 6H), 3.16 (s, 1H), 3.05 (s, 2H), 2.81 (s, 3H), 2.72 (s, 3H), 
2.19 (d, J = 15.3 Hz, 1H), 1.97 (s, 1H), 1.65 – 1.53 (m, 3H), 1.49 – 1.23 (m, 4H), 0.86 (t, J = 7.4 
Hz, 3H), 0.73 (t, J = 7.3 Hz, 3H). HRMS calculated for C43H57N5O7 [M + 2H]
2+ 377.7124, found 
377.7140. LC/MS (Method A): (electrospray +ve), m/z 754.3 (MH)+, tR = 3.802, UV254 > 98%. 
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N-(1-benzylpiperidin-4-yl)-6,7-dimethoxy-2-(4-methyl-1,4-diazepan-1-yl)quinazolin-4-
amine (BIX-01294) 
 
 
HRMS calculated for C28H39N6O2 [M + H]
+ 491.3129, found 491.3119. LC/MS (Method A): 
(electrospray +ve), m/z 491.3 (MH)+, tR = 3.199, UV254 > 98%. 
 
(R)-N-(1-(3-(1-benzoyl-3-(3,4-dichlorophenyl)piperidin-3-yl)propyl)-4-phenylpiperidin-4-
yl)-N-methylacetamide (Hh-Ag1.5) 
 
 
HRMS calculated for C28H27ClF2N3OS [M + H]
+ 526.1526, found 526.1532. LC/MS (Method 
A): (electrospray +ve), m/z 526.1 (MH)+, tR = 4.048, UV254 > 98%. 
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4-((4-fluoro-2-methyl-1H-indol-5-yl)oxy)-6-methoxy-7-(3-(pyrrolidin-1-
yl)propoxy)quinazoline (Cediranib) 
 
 
1H NMR (400 MHz, DMSO-d6) δ 11.34 (d, J = 2.4 Hz, 1H), 8.49 (s, 1H), 7.60 (s, 1H), 7.38 (s, 
1H), 7.16 (d, J = 8.6 Hz, 1H), 6.98 (dd, J = 8.6, 7.4 Hz, 1H), 6.24 (d, J = 2.0 Hz, 1H), 4.25 (t, J = 
6.4 Hz, 2H), 3.99 (s, 3H), 2.58 (t, J = 7.1 Hz, 2H), 2.46 (m, 5H), 2.41 (s, 3H), 1.99 (dd, J = 7.9, 
5.7 Hz, 2H), 1.70 (s, 3H). HRMS calculated for C25H28FN4O3 [M + H]
+ 451.2140, found 
451.2130. LC/MS (Method A): (electrospray +ve), m/z 451.1 (MH)+, tR = 4.353, UV254 > 98%. 
 
(R)-N-(1-(3-(1-benzoyl-3-(3,4-dichlorophenyl)piperidin-3-yl)propyl)-4-phenylpiperidin-4-
yl)-N-methylacetamide (Osanetant) 
 
 
HRMS calculated for C35H42Cl2N3O2 [M + H]
+ 606.2649, found 606.264. LC/MS (Method A): 
(electrospray +ve), m/z 606.2 (MH)+, tR = 5.399, UV254 > 98%. 
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5-(3-(benzyloxy)phenyl)-7-(3-(pyrrolidin-1-ylmethyl)cyclobutyl)-7H-pyrrolo[2,3-
d]pyrimidin-4-amine (NVP-ADW742) 
 
 
1H NMR (400 MHz, DMSO-d6) δ 8.12 (s, 1H), 7.65 (s, 1H), 7.51 – 7.44 (m, 2H), 7.45 – 7.29 (m, 
4H), 7.15 (t, J = 2.0 Hz, 1H), 7.11 – 7.04 (m, 1H), 7.04 – 6.96 (m, 1H), 6.10 (s, 2H), 5.31 (p, J = 
8.3 Hz, 1H), 5.17 (s, 2H), 2.72 – 2.58 (m, 4H), 2.47-2.44 (m, 5H), 2.25 (ddd, J = 12.1, 8.5, 2.9 
Hz, 2H), 1.74 – 1.62 (m, 4H). HRMS calculated for C28H32N5O [M + H]+ 454.2601, found 
454.2615. LC/MS (Method A): (electrospray +ve), m/z 454.2 (MH)+, tR = 4.106, UV254 > 98%. 
 
(E)-4-(1-(4-(2-(methylamino)ethoxy)phenyl)-2-phenylbut-1-en-1-yl)phenol (Endoxifen) 
 
 
1H NMR (400 MHz, DMSO-d6, major isomer) δ 9.17 (s, 1H), 7.17 (t, J = 7.6 Hz, 2H), 7.08 (d, J 
= 8.9 Hz, 5H), 6.92 (d, J = 8.2 Hz, 2H), 6.59 (d, J = 8.2 Hz, 2H), 6.39 (d, J = 8.1 Hz, 2H), 4.01 
(t, J = 5.6 Hz, 2H), 2.82 (t, J = 5.6 Hz, 2H), 2.39 (q, J = 7.3 Hz, 2H), 2.34 (s, 3H), 0.84 (t, J = 7.3 
Hz, 3H). HRMS calculated for C25H28NO2 [M + H]
+ 374.2115, found 374.2105. LC/MS (Method 
A): (electrospray +ve), m/z 374.1 (MH)+, tR = 5.001, UV254 = 60.6% (major isomer). 
 
 
51 
 
 
11-(3,4-dimethylbenzyl)-3,7-dimethyl-3,7,11-triazaspiro[5.6]dodecane (ZINC67869167) 
 
 
HRMS calculated for C20H34N3 [M + H]
+ 316.2747, found 316.2757.  
 
((3R,4R)-1-((2,3-dimethyl-1H-indol-7-yl)methyl)-4-(pyrrolidin-1-ylmethyl)pyrrolidin-3-
yl)methanol (ZINC91973695) 
 
 
HRMS calculated for C21H32N3O [M + H]
+ 342.254, found 342.2532.  
 
1.6.3.b Cell culture methods  
HeLa and HEK293 cells were purchased from the American Type Culture Collection 
(ATCC, Manassas, VA, USA). The cells were cultured in DMEM supplemented with 10% fetal 
bovine serum (FBS, GE healthcare, Piscataway, NJ, USA) and 100 U/mL of penicillin and 100 
µg/mL of streptomycin (Life Technologies, Carlsbad, CA, USA) at 37 °C in a humidified 
atmosphere with 5% CO2. Cells were passaged at 90% confluency. 
1.6.3.c Ebola VLP beta-lactamase assay for HTS in 1536-well plates  
A chemical biology screening campaign was performed. Ebola VLP assay was conducted 
as previously described.7 Briefly, HeLa cells were seeded at 750 cells/well in 3 µL of assay 
medium (DMEM+10% FBS) in 1536-well assay plates. Compounds were prepared in a 1536-well 
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compound plate, and 23 nL of each compound was transferred into 1536-well assay plate using an 
NX-TR pintool station (WAKO Scientific Solutions, San Diego, CA, USA). After 1 h incubation 
at 37 °C with 5% CO2, 1 µL/well of VLP solution was added to the assay plates using a BioRapTR 
FRD dispenser. The plates were then spinoculated, followed by incubation at 37 °C with 5% CO2 
for 4.5 h. 1 µL CCF2-AM beta-lactamase substrate was added in to each well, and the plates were 
incubated for 2 h at room temperature. The assay was detected at dual fluorescence intensities 
(Ex1= 405±20, Em1= 460±20, and Ex2= 405±20, Em2= 530±20 nm) using EnVision plate reader 
(PerkinElmer, Boston, MA, USA). 
1.6.3.d Cell viability assay with the ATP content assay kit  
The cell viability assay was performed as previously described.7 Briefly, HeLa and 
HEK293 cells were plated at 750 cells/well in 3 µL in 1536-well assay plates, followed by the 
addition of tested compounds at 23 nL/well. After a 4.5 h incubation at 37 °C and 5% CO2, cell 
viability was measured by adding 3 µL of ATP content assay mixture to each well. Luminescence 
values were obtained using a ViewLux plate reader (PerkinElmer, Boston, MA, USA). 
1.6.3.e Ebola live virus assays 
Vero E6 cells were plated in the 96-well plate (black with optical bottom). Briefly, serial 
dilutions of 5 drugs (diluted in DMEM 2% FBS starting at 10 µM) and DMSO as control, were 
added to the wells, and incubated for 1 h at 37 °C with 5% CO2. The cells were infected with 
EBOV/Mayinga-eGFP at a MOI of 0.1 TCID50/cell. The assay was run in triplicate at a biosafety 
level-4 (BSL-4) facility. The fluorescence was read 72 h after infection using a BioTek Synergy 
HT. 
1.6.3.f Filipin staining and LysoTracker-red staining  
The assays were performed as previously described.54 Fibroblast cells were plated at 1,000 
cells/well in 4 µL of assay medium (DMEM + 10% FBS) in 1536-well assay plates and incubated 
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overnight at 37 °C and 5% CO2. Compounds were added to the assay plate at 23 nL/well. After 24 
h incubation at 37 °C and 5% CO2, 2 µl/well of 50 ng/ml filipin or 0.5 µM LysoTracker Red DND-
99 was added to the plate. After 1 hr. incubation at 37 °C and 5% CO2, the plates were washed 
twice. The fluorescence intensities were then read with a fluorescence plate reader (GE Healthcare, 
Chicago, Illinois, USA). U18666A [3-β-(2-[diethylamino]ethoxy)-androst-5-en-17-one, 
monohydrochloride] was used as the positive control.55 
1.6.3.g Cathepsin B/L assay  
Cathepsin B/L assays were performed as previously described.8 Briefly, recombinant 5 ng 
of cathepsin B, or cathepsin L were added into each well in 384-well plate. Indicated drugs were 
added into the recombinant enzymes, followed by initiation of the reaction by addition of 
fluorescent substrate. The activity measurements were done using Tecan plate reader (Tecan US, 
Inc., Morrisville, NC, USA). Cathepsin L inhibitor and ED64 were used as positive controls.8 
1.6.3.h Thermal shift binding assay with Ebola VLP  
The thermal shift binding assay was performed as previously described.16 Ebola VLPs were 
pre-incubated with indicated drugs for 10 min at room temperature. The mixture was then 
subsequently heated at 49 °C for 3 min, followed by centrifugation at 13, 000 x g at 4 °C for 20 
min. The supernatant was collected and denatured by heating at 75 °C for 10 min in the presence 
of SDS loading buffer (Life Technologies, Carlsbad, California, United States). The samples were 
separated by SDS-PAGE gel electrophoresis and detected by anti-beta-lactamase antibodies (Life 
Technologies, Carlsbad, California, United States).  
1.6.3.i Data analysis and statistics  
Half maximal inhibitory concentration (IC50) values of compound activity data were 
calculated using Prism software (GraphPad Software, Inc. San Diego, CA). All values were 
expressed as the mean ± SEM (n ≥3). 
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1.7 ASSOCIATED CONTENT 
Supporting Information. Supplementary Files 1-15 are available at 
https://scapuzzi.web.unc.edu/free-downloads/ 
Additionally, all the datasets and Chembench models are provided in and on the 
Chembench Web-Portal (https://chembench.mml.unc.edu/), which provides public access and use 
of data and models used in this study. The P1, P2, HEK, and HeLa training sets are publicly 
indexed as “Ebola_SM1” and “Ebola_PCM4”, “151105_Ebola_Toxicity_HEK”, and 
“151105_Ebola_Toxicity_HELA”, respectively. The Chembench P1, P2, and HeLa models are 
publicly indexed as “153004_ebola_Strict_Model1_166_DragonH”, 
“151305_ebola_1224_PCM4”, and “151105_ebola_tox_HeLa”, respectively.   
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CHAPTER 2: COMPUTATIONAL DISCOVERY AND EXPERIMENTAL 
VALIDATION OF POTENT INHIBITORS OF THE UNDERSTUDIED KINASE DCLK1 
2.2 INTRODUCTION  
Doublecortin-like kinase 1 (DCLK1) has been implicated in the development and 
progression of several cancers.56,57 Recent studies have shown that DCLK1, which is also referred 
to as DCAMKL-1, drives tumorigenesis in colon and pancreatic cancer58,59, is overexpressed in 
cancers of the liver and esophagus60,61, and such overexpression is an adverse prognosis factor in 
bladder and non-small cell lung cancer62,63. Notably, in 2013, Nakanishi et al. showed that DCLK1 
expression uniquely distinguished tumor stem cells (TSCs) in colorectal cancer from healthy stem 
cells and demonstrated that specific ablation of DCLK1-positive TSCs reduced tumor size without 
damaging healthy tissue.64 Given these observations, DCLK1 represents an emergent therapeutic 
target in oncology, especially, for colorectal cancer. 
Despite its growing notoriety in oncology, DCLK1 is still considered as an understudied 
kinase65 lacking any potent and moderately selective tool compounds. As per the guidelines for 
inclusion into the Structural Genomic Consortium’s comprehensive kinase chemogenomics set 
(KGCS), DCLK1 remains a dark, or chemically untargeted, protein kinase.66  A chemical probe 
for DCLK1 would be of great scientific and therapeutic value, as it could help unravel the specific 
biological role of this kinase in various cancers and serve as a potential lead for drug discovery 
efforts.67,68 
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The development of a chemical probe is dependent upon the identification of high quality 
chemical starting points for potency and selectivity optimization.66 This process is particularly 
challenging for dark kinases like DCLK1, where chemogenomics data and SAR studies are limited 
and often the unintended consequence of screening campaigns for other kinases. Indeed, the 
handful of compounds in the literature that target DCLK1 have come mainly from a kinome-wide 
screen of inhibitors bearing pyrimido-diazepine scaffolds69 or have been reported as an off-target 
effect during probe development for other kinases such as, ACK1, ERK5, and LRRK2.69–71 The 
development of novel DCLK1 inhibitors is critical to progress probe development for this 
biomedically-relevant, but, so far, dark kinase.  
Methods of computer-aided drug design (CADD) are routinely used to leverage prior 
screening data towards the discovery of novel bio-active compounds while also reducing time and 
cost. CADD approaches are most effective when large and diverse chemogenomics sets are 
available. Unfortunately, for DCLK1, experimental screening datasets are small (less than 100 
compounds have been tested so far), most compounds are inactive, and active molecules are very 
limited in chemical diversity.69 According to best practices previously established by us and 
others,9,72 it is not advisable to employ CADD approaches, especially QSAR modeling, for such 
datasets, as the potential for faulty predictions is high. At the same time, we were confronted by 
the therapeutic importance of this dark kinase, a lack of tool compounds, and the expressed need 
to prioritize laborious synthetic efforts presented by the diversity of synthetically feasible 
compounds. We were thus motivated to apply our expertise in modeling challenging datasets40,47,73 
in an attempt to discover potent DCLK1 inhibitors in close collaboration with our experimental 
partners. 
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In order to accomplish this goal, we executed the following steps: (i) the development of 
QSAR models of DCLK1 inhibition from prior screening data; (ii) virtual screening of focused 
chemical libraries to identify putative DCLK1 inhibitors; (iii) experimental validation of selected 
compounds; and (iv) off-target selectivity analyses for experimentally confirmed hits.   
Once several high-quality DCLK1 inhibitors were identified, we then (v) derived structural 
rules and key molecular interactions to guide future design and optimization efforts of these 
compounds using the cheminformatics techniques of matched molecular pair analysis, QSAR 
model interpretation, and molecular docking. This joint modeling and experimental effort (Figure 
2.1) resulted in the discovery of some of the most potent DCLK1 inhibitors to-date. These 
compounds constitute leads for the development of a chemical probe for this dark kinase. 
 
 
2.3 RESULTS 
2.3.1 QSAR Model Development   
Modelability Index (MODI),44 which affords rapid estimation of the feasibility of obtaining 
predictive QSAR models, was calculated for both training sets. MODI values of 0.79 and 0.89 
were obtained for the KINOMEscan and KiNativ training set, respectively. These MODI values 
were well-above the recommended threshold of 0.65, indicating that despite a high degree of 
Figure 2. 1. Overall study design. The workflow combines computational and experimental 
medicinal chemistry approaches for the discovery for novel potent DCLK1 compounds. 
 
Table 2.1.Statistical characteristics obtained on 5-fold external CV of all models 
developed in this study.Figure 2. 2. Overall study design. The workflow combines 
computational and experimental medicinal chemistry approaches for the discovery for novel 
potent DCLK1 compounds. 
 
Table 2.2.Statistical characteristics obtained on 5-fold external CV of all models developed 
in this study.  
 
Figure 2. 3. Four scaffolds (A-D) based on the pyrimido-diazepine core (purple) possessed 
by compounds in the modeling datasets. Note A-C are 1,4-diazepines, while D is a 1,3-
diazepine.Table 2.3.Statistical characteristics obtained on 5-fold external CV of all models 
developed in th s study.Figure 2. 4. Overall stu y design. The workflow com ines 
computational and experimental medicinal chemistry approaches for the discovery for novel 
otent DCLK1 co pounds. 
 
Table 2.4.Statistical characteristics obtained on 5-fold external CV of all models 
developed in this study.Figure 2. 5. Overall study design. The workflow combines 
computational and experimental medicinal chemistry approaches for the discovery for novel 
potent DCLK1 compounds. 
 
Table 2.5.Statistical characteristics obtained on 5-fold external CV of all models developed 
in this study.  
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imbalance towards inactive compounds and limited chemical diversity there was meaningful SAR 
that separates actives from inactives.   
Next, we moved to model development and succeeded in developing robust and externally 
predictive QSAR models. Results of 5-fold external cross-validation are presented in Table 2.1. 
All metrics used to evaluate model performance were above the recommended threshold of 0.60. 
As such, these metrics demonstrated that active and inactive DCLK1 compounds can be correctly 
classified through statistically meaningful SAR.   
 
 
 
 
Since externally-validated and predictive QSAR models were developed using all available 
data, the applicability domain (AD) of the models was maximized, as the imbalanced datasets did 
not need to be down-sampled.40 Both the KINOMEscan and KiNativ models were predictive and 
useful for virtually screening new compounds in so far as these compounds fell within the AD that 
has been maximized by using all available data. In order to demonstrate that the models were not 
Model Name Actives Inactives Total CCR SE SP PPV NPV 
KINOMEscan 8 45 53 0.84 0.75 0.92 0.62 0.95 
KiNativ 5 42 47 0.73 0.70 0.75 0.61 0.96 
Table 2.33.Statistical characteristics obtained on 5-fold external CV of all models 
developed in this study.  
 
Figure 2. 41. Four scaffolds (A-D) based on the pyrimido-diazepine core (purple) 
possessed by compounds in the modeling datasets. Note A-C are 1,4-diazepines, while D is 
a 1,3-diazepine.Table 2.34.Statistical characteristics obtained on 5-fold external CV of all 
models developed in this study.  
 
Figure 2. 42. Four scaffolds (A-D) based on the pyrimido-diazepine core (purple) 
possessed by compounds in the modeling datasets. Note A-C are 1,4-diazepines, while D is 
a 1,3-diazepine.   
 
Figure 2. 43. Four scaffolds (A-D) based on the pyrimido-diazepine core (purple) 
possessed by compounds in the modeling datasets. Note A-C are 1,4-diazepines, while D is 
a 1,3-diazepine.Table 2.35.Statistical characteristics obtained on 5-fold external CV of all 
models developed in this study.  
 
Figure 2. 44. Four scaffolds (A-D) b sed on the pyrimido-diazepine core (purple) 
possessed by compounds in the modeling datasets. Note A-C are 1,4-diazepines, while D is 
a 1,3-diazepine.Table 2.36.Statistical characteristics obtained on 5-fold external CV of all 
models developed in this study.  
 
Figure 2. 45. Four scaffolds (A-D) based on the pyrimido-diazepine core (purple) 
possessed by compounds in the modeling datasets. Note A-C are 1,4-diazepines, while D is 
a 1,3-diazepine.   
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obtained because of random SAR correlation between bioactivity and chemical descriptors, 1000 
rounds of Y-randomization was performed. All Y-randomized models showed a CCR below 0.60.   
2.3.2 QSAR-Based Virtual screening 
A set of 169 designed compounds possessing the same scaffolds as in Figure 2.2 was 
virtually screened with both QSAR models (See Methods). Although all 169 compounds were 
within the AD of both models, only seven compounds were predicted as active by both models. 
All seven compounds possessed the 5,11-dihydro-6H-benzo[e]pyrimido[5,4-b][1,4]diazepin-6-
one scaffold (Figure 2.2B). The remaining compounds were either predicted active only by the 
KINOMEscan model (29 compounds) or the KiNativ model (two compounds); 131 compounds 
were predicted inactive by both models. These results are consistent with the distribution between 
actives and inactives in the training sets, supporting the notion that DCLK1 has highly specific 
requirements to compound structure to make it active. From the compounds that did not meet the 
“hit” criteria, four were selected as negative controls for the model validation. Ultimately, 11 
compounds, seven putatively active and four predicted inactive, were selected for experimental 
studies. Virtual screening results for all compounds are provided in the Supporting Information 
(Supplementary Table 1).   
 
Figure 2.2. Four scaffolds (A-D) based on the pyrimido-diazepine core (purple) possessed 
by compounds in the modeling datasets. Note A-C are 1,4-diazepines, while D is a 1,3-
diazepine.   
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2.3.3 Experimental Validation  
A threshold of activity for the 11 compounds from the virtual screening was set at 10 μM, 
as both models were developed from compounds screened at this concentration. The IC50 values 
and the structures of these 11 compounds are shown in Table 2.2. These results show that QSAR 
models were ~73% accurate, as they correctly predicted the activity calls for 8 out of 11 
compounds. Of the seven putative DCLK1 hits, six had IC50 < 10 μM, including four sub-
micromolar inhibitors. The top hit, XMD13-44, had an IC50 of 52 nM. Two of the four putatively 
inactive compounds were incorrectly classified, but, ironically, in this case of negative controls, 
the inaccuracy is a desired outcome. Statistically, however, this observation is expected for the 
imbalanced dataset modeling.74 Overall, eight compounds from the virtual screen had IC50 < 10 
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μM for DCLK1. Full dose-response curves are available in Figure 2.3. 
 
 
Figure 2. 73. Dose-response curves for the eleven virtual screening hits.  
 
Figure 2. 74. Dose-response curves for the eleven virtual screening hits.  
 
Figure 2. 75. Dose-response curves for the eleven virtual screening hits.  
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The selectivity profiles of the eight compounds with IC50 < 10 μM for DCLK1 were 
determined using a KiNativ screen (Table 2.3). The compounds were evaluated both by the 
selectivity index (SI) at 65% and 90% inhibition at 10 μM, i.e., SI(65) and SI(90), respectively. 
The Structural Genomics Consortium (SGC) has previously defined SI(65) < 4.0% and SI(90) < 
2.0% as acceptable selectivity profiles for a tool compound to be considered for inclusion into their 
comprehensive kinase chemogenomics set (KCGS).66 Only XMD13-37 inhibited more than 4% of 
kinases screened according to SI(65). On the other hand, all eight compounds had acceptable 
SI(90) profiles. KiNativ screen data are provided for the eight compounds in the Supporting 
Information (Supplementary Table 2).  
2.3.4 SAR Analysis and Implications for Future Design  
All of the experimentally validated hits possessed the 5,11-dihydro-6H-
benzo[e]pyrimido[5,4-b][1,4]diazepin-6-one scaffold, and the four most potent hits shared 
common structural moieties (Table 2). In order to gain insights about structural aspects and key 
molecular interactions associated with DCLK1 inhibition among these compounds, as well as to 
guide future design and optimization efforts, SAR analysis was performed using several 
cheminformatics techniques.  
2.3.4.a Matched Molecular Pair Analysis and Model Interpretation  
The modeling datasets were investigated for matched molecular pairs (MMPs) bearing the 
5,11-dihydro-6H-benzo[e]pyrimido[5,4-b][1,4]diazepin-6-one scaffold. From the KINOMEscan 
dataset, a series of MMPs was identified with several activity cliffs, i.e., structurally similar 
compounds from different activity classes.75,76 The shared scaffold of the MMPs and 
accompanying structural changes are shown in Figure 2.4. Within this series of compounds, only 
XMD8-85 and XMD8-87 were active; therefore, the remaining associated MMPs constitute 
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activity cliffs. This analysis revealed that the presence of a methoxy substituent at R1 and a co-
occurring methyl substituent at R2 correlated with increased DCLK1 inhibition.  
On the other hand, the influence of the R3 substituent was unclear, as active compounds 
XMD8-85 and XMD8-87 are MMPs differing only at this position. Fragment descriptor 
interpretation (Figure 2.5) from the KINOMEscan QSAR model, however, showed that the methyl 
addition at R3 increased the overall active (inhibitory) character of XMD8-85 relative to XMD8-
87. The SAR elucidated by the MMP analysis was also reflected by the model interpretation, as 
methoxy substituents at R1 and methyl substituents at R2 increased the activity profile in 
descriptor space.  
2.3.4.b Molecular Docking 
Training set compounds were docked into the crystal structure of DCLK1 (PDB: 5JZN)57 
in order to evaluate and validate the molecular docking approach. All training set actives, with the 
exception of just one compound, ranked within the top 15% of the best scored docking poses 
(Supplementary Table 3). This enrichment of training set actives among the best scored docking 
poses provided validation for the use docking as a method to generate hypotheses related to the 
protein-ligand interactions for the 11 compounds from the virtual screen. For these 11 compounds, 
the molecular docking scores correlated well with the experimentally-determined potencies. 
Indeed, the two most potent compounds, XMD13-44 and XMD8-90, had the best two docking 
scores (-7.75 and -7.69), respectively. XMD10-100, inactive upon experimental testing, likewise, 
had the second worst docking score (-4.72). TL-1-060, the compound with the worst docking score 
(-4.53), was only weakly potent (9.60 μM). All scores and poses for these 11 compounds are 
provided in the Supporting Information (Supplementary Table 3).   
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2.4 DISCUSSION  
Despite small dataset sizes with limited chemical diversity and a small number of active 
compounds, robust and predictive QSAR models of DCLK1 inhibition were developed from the 
results of KINOMEscan and KiNativ assays (Table 2.1). On further inspection, these training set 
characteristics were, in fact, crucial for successful QSAR model development. The limited 
chemical diversity in terms of scaffolds (Figure 2.2) among the training sets meant that large 
changes in DCLK1 bioactivity were caused by slight modifications in a small number of 
substituents. This observation was supported by the high MODIs of the training sets, which 
indicated that there was statistically meaningful SAR separating active compounds from inactive 
compounds. Both the MMP and model interpretation analyses also reflected this observation 
(Figures 2.3 and 2.4), as both showed that the activity profile was modulated by a few substituents 
at key sites. The successful development of QSAR models for DCLK1 inhibition from small and 
highly congeneric compounds harkens back to the early days of QSAR modeling and underscores 
the continuing need to carefully inspect modeling datasets, through methods like MODI, prior to 
modeling.  
After models were built and validated, they were used to virtually screen compounds 
bearing the same scaffolds as in Figure 2.2, resulting in the most potent series of DCLK1 inhibitors 
to date. Ultimately, six out of seven compounds prioritized by QSAR modeling as DCLK1 
inhibitors had IC50 values < 10 μM, and four of these were sub-micromolar inhibitors (Table 2.2). 
On the other hand, two compounds predicted to be inactive by the models, JWE-067 and JWE-
041, were shown experimentally to inhibit DCLK1 (Table 2.2). Since the goal of any drug 
discovery campaign is to identify compounds with the desired biological profile, in this case 
DCLK1 inhibition, ironically, this misclassification is not a failure.  
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Overall, eight compounds from the virtual screen, all of which possessed the 5,11-dihydro-
6H-benzo[e]pyrimido[5,4-b][1,4]diazepin-6-one scaffold, had IC50 < 10 μM, including five sub-
micromolar inhibitors (see Table 2.2). XMD13-44, a 52 nM inhibitor, was the most potent 
compound identified through virtual screening, which highlights that these models are capable of 
not only classifying inhibitors (actives) from non-inhibitors (inactives), but also of identifying 
highly potent compounds within the same chemical series. By any measure, the hit-rate from 
QSAR-based virtual screening of compounds (~73%) is enriched in comparison to the ~13% 
active-calls from the preliminary kinome screens of these same scaffolds (Table 2.1).  
Chemical probe development also requires selectivity against off-targets.67,77 The 
selectivity profiles of the eight compounds with IC50 < 10 μM for DCLK1 were assessed and 
quantified according to SI(65) and SI(90) (Table 2.3). These selectivity indices are a measure of 
a compound’s kinome promiscuity at certain thresholds of inhibition. For a compound to be 
considered for possible inclusion into the KCGS developed by the SGC, in addition to sufficient 
on-target potency, the compound ought to have SI(65) < 4.0% and SI(90) < 2.0%.66  All eight 
potent DCLK1 inhibitors were screened against at least 239 additional kinases. Only XMD13-37 
did not meet the SI(65) criterion, as it inhibited more than 4% of kinases screened. The most potent 
DCLK1 inhibitor, XMD13-44, had an acceptable selectivity profile, inhibiting the enzymatic 
activity of only three off-target kinases by more than 65% (Supplementary Table 2). The five 
sub-micromolar DCLK1 inhibitors, therefore, could be considered useful tool compounds in the 
KCGS and high-quality starting points for further probe optimization efforts. It should be noted, 
however, that compounds with this scaffold have been previously reported to competitively inhibit 
LRRK2,71 ERK5,70,78 Aurora A/B,79 and PI3K-δ/γ kinases80 and to bind to BRD4 bromodomains80. 
Indeed, the most potent DCLK1 inhibitor, XMD13-44, inhibited ERK5 by more than 90% 
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(Supplementary Table 2). Optimizing DCLK1-selective compounds from this scaffold is, 
therefore, an on-going effort.70,80,81   
To this end, SAR analyses were performed to inform optimization efforts through the 
identification of chemical structures and key protein-ligand interactions that drive DCLK1 
inhibition. Cheminformatics approaches, i.e., MMP analysis, QSAR model interpretation, and 
molecular docking, provided hypotheses about the underlying chemical features and molecular 
interactions that drive DCLK1 inhibition for lead compounds bearing the 5,11-dihydro-6H-
benzo[e]pyrimido[5,4-b][1,4]diazepin-6-one scaffold. These cheminformatics approaches can 
also be applied to design and optimize follow-up compounds for both potency and off-target 
selectivity considerations.   
In the present study, MMP analysis and model interpretation of fragment descriptors of 
compounds both in the training set and in the experimentally validated set revealed useful 
structural insights. For certain compounds possessing the 5,11-dihydro-6H-benzo[e]pyrimido[5,4-
b][1,4]diazepin-6-one scaffold (Figure 2.2), a methoxy substituent to the phenyl ring (R1) and two 
co-occurring methyl substituents at R2 and R3 on the diazepine ring were shown to correlate with 
DCLK1 inhibition. The two most potent hits identified from the virtual screening, XMD13-44 and 
XMD8-90, align with this observation, as both compounds possess these features at R1, R2, and 
R3. Similarly, two inactive compounds lack some of these features: XMD11-100 lack methyl 
substituents at R2 and R3, while XMD11-40-2 lacks the methyl group at R2, though both 
compounds have a methoxy group at R1. Fragment descriptor analysis indicated that a substituent 
at the R3 position promoted DCLK1 inhibition (Figure 2.3) and may be considered a possible site 
for future optimization.   
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While the SAR trends around these three positions correlate with DCLK1 inhibition, not 
all of them are necessarily required for the desired activity and potency. For instance, the highly 
potent compound TL-1-038 (109 nM) does have two co-occurring methyl substituents at R2 and 
R3 on the diazepine ring, but lacks the methoxy group at R1. These derivations from the SAR 
trends highlight the importance of multivariate features in molecular design, as TL-1-038 
possesses a piperidinol group attached to the aniline moiety that is unique among all hits. In fact, 
potent inhibitors XMD13-44, XMD8-90, and TL-1-038 all differ at this tail region off of the aniline 
moiety (Table 2.2), making it a possible site for further medicinal chemistry efforts.   
Molecular docking provided additional insights to SAR trends among MMPs.82 XMD10-
39, a 154 nM inhibitor, differs from training set active compound XMD8-85 and from training set 
inactive XMD10-78 by a single ethyl substitution at R2. This observation indicates that, for the 
most part, both methyl and ethyl substitutions at the R2 position are tolerated for DCLK1 
inhibition, whereas an isopropyl is not. This slight change in structure that results in a large change 
in activity is reflected by the molecular docking results (Figure 2.6), which shows that the binding 
pose of inactive XMD10-78 (red) is flipped in the ATP-binding site relative to active compounds 
XMD8-85 (teal) and XMD10-39 (green). It is worth noting that JWE-067 (0.265 μM) possesses 
an isopropyl substitution at the R2 position; however, its structure and binding pose are 
considerably different from the MMPs mentioned above (SI).  
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Docking provided additional hypotheses about the key protein-ligand interactions for other 
DCLK1 inhibitors. Using the two most potent compounds as examples, which also have the two 
best docking scores, key hydrogen-bonds are likely formed with the backbone of the hinge-region 
valine in the ATP-binding by the 3-position pyrimidine nitrogen and the aniline NH site (Figure 
2.7).  
The recommended modifications to the four most potent lead compounds, i.e., XMD13-
44, XMD8-90, XMD10-39, and TL-1-038 (Table 2.2), are summarized in Figure 2.8.  Based on 
the SAR analysis, a methoxy substitution at R1 paired with either a methyl or ethyl substitution at 
R2 promotes DCLK1 inhibition (Figure 2.2).  A methyl substituent at the R3 position is present 
in all four lead compounds (Table 2.2) and was shown to promote DCLK1 inhibition among 
training set MMPs (Figure 2.3).  At minimum, a methyl substituent at this position is required. 
Docking studies also suggest that additional hydrogen bonds may be formed by larger chemical 
Figure 2.6 
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substituents at R3 and residues in the pocket (Figure 2.7). This site should be considered for further 
optimization and SAR studies. Finally, the R4 region off of the aniline moiety is varied among the 
leads and the training set MMPs, making it another possible site for optimization and combinatorial 
design.   
 
 
 
 
2.5 CONCLUSIONS 
The integration of QSAR-based virtual screening and experimental medicinal chemistry 
(Figure 1.1) used in this study resulted in the discovery of the most potent and selective series of 
DCLK1 inhibitors to date. We succeeded to develop robust and predictive QSAR models of 
DCLK1 inhibition, despite challenges in the available data, which included limited dataset sizes 
and a very small amount of active compounds. These models were used hen to screen a set of 169 
compounds. Ultimately, five sub-micromolar inhibitors with a 5,11-dihydro-6H-
benzo[e]pyrimido[5,4-b][1,4]diazepin-6-one scaffold were identified using this approach. The top 
hit, XMD13-44, had an IC50 of 52 nM. Subsequent cheminformatics-based SAR analyses 
Figure 2.7104. SAR analysis and implications for 
design. Recommended modifications to the four most 
potent lead compounds at positions R1-R4 are shown. 
Sites known to modulate DCLK1 activity are shown in 
green. Sites proposed for DCLK1 optimization are 
shown in orange.   
 
Figure 2.105. SAR analysis and implications for 
design. Recommended modifications to the four most 
potent lead compounds at positions R1-R4 are shown. 
Sites known to modulate DCLK1 activity are shown in 
green. Sites proposed for DCLK1 optimization are 
s own in orange.   
 
Figure 2.106. SAR analysis and implications for 
design. Recommended modifications to the four most 
potent lead compounds at positions R1-R4 are shown. 
Sites known to modulate DCLK1 activity are shown in 
green. Sites proposed for DCLK1 optimization are 
shown in orange.   
 
Figure 2.107. SAR analysis and implications for 
design. Recommended modifications to the four most 
potent lead compounds at positions R1-R4 are shown. 
Sites known to modulate DCLK1 activity are shown in 
green. Sites proposed for DCLK1 optimization are 
shown in orange.   
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demonstrated that the activity of these compounds depends on certain of structural features. The 
selectivity profiles of these potent inhibitors against off-target kinases demonstrated their potential 
utility as DCLK1 tool compounds, though further optimization efforts are currently on-going.  
Joint modeling and experimental efforts such as those presented here may help accelerate the rate 
of discovery among dark and understudied kinases. Our study demonstrates that even despite the 
obvious lack of data for understudied targets, integration of computational and experimental 
approaches accompanied by close interaction and collaboration between modeling and medicinal 
chemistry groups can lead to the discovery of potent inhibitors. The significant advantage of this 
methodology is its easy translation to other kinases and targets, dark or otherwise, for future 
discovery efforts.  
2.6 METHODS 
2.6.1 Data Production, Collection, Curation, and Classification  
Compounds were synthesized and screened in KINOMEscan83 and KiNativ84 assays. 
Compounds tested in these screens feature four scaffolds based on a common pyrimido-diazepine 
core (Figure 2.2 A-D).69   
A total of 53 compounds were tested in a kinome-wide screen (>200 kinases) at 10 μM by 
the KINOMEscan assay. Briefly, KINOMEscan is a competition-based assay in which the kinase 
of interest is either baited to an immobilized bead by interacting with an active-site directed small 
molecule or displaced from the bead by binding to the test compound. Compounds with 
experimental values less than or equal to 1%, i.e., 1% of the kinase not displaced, were considered 
“active”, while all compounds with values greater than 1% were considered “inactive”. This 
compound classification resulted in 8 actives and 45 inactives for DCLK1.   
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A total of 47 compounds were tested in the KiNativ assay in a kinome-wide screen (>200 
kinases) at 10 μM. KiNativ is a binding assay in which pretreatment of a kinase with the test 
compound prevents a covalent interaction between the kinase and a standard probe to take place. 
Compounds with greater or equal to 50% inhibition were considered “active”, while all compounds 
with less than 50% inhibition were considered “inactive”. This compound classification resulted 
in 5 actives and 42 inactives for DCLK1.  
 
Eleven compounds were tested in both the kinome-wide profiling KINOMEscan and 
KiNativ assays, with an approximately 82% concordance in classification for activity against 
DCLK1 (Supplementary Table 4). However, due to an insufficient amount of overlap between 
the two assays, data were not integrated. Instead, two separate models were developed. Prior to 
modeling, all compounds were curated according to our well-established protocols.36–38 Training 
set compounds are available as sdf files in the Supporting Information (Supplementary Files 1 and 
2)  
2.6.2 Computational Methods 
Following the best practices of QSAR modeling advanced earlier by our group,9 two 
independent models, i.e., for KINOMEscan and KiNativ data, were developed using the GUSAR 
modeling package85,86. GUSAR is a proprietary software; however, models are available in the 
Supporting Information (Supplementary Files 3 and 4) and could be used by anyone possessing 
the software package.   
2.6.2.a Molecular descriptors 
GUSAR uses a combination of whole-molecule descriptors and 2D fragment 
descriptors.85,86 The whole-molecule descriptors generated by GUSAR are topological length and 
volume; lipophilicity; molecular weight; and numbers of aromatic and halogen atoms, positive and 
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negative charges, and hydrogen bond donors and acceptors. The 2D fragment descriptors are of 
two types: multilevel neighborhoods of atoms (MNA)27 descriptors and quantitative 
neighborhoods of atoms (QNA) 28. 
2.6.2.b RBF-SCR algorithm  
In this machine-learning algorithm, descriptors are weighted during the calculation of the 
radial basis function (RBF) by the coefficients obtained from self-consistent regression (SCR).87 
These coefficients reflect the contribution of each particular descriptor to the final equation for the 
given activity. The absolute value of the coefficient corresponds to its contribution. In the RBF-
SCR method, the weights for each descriptor vector used for the calculation of RBF are based on 
that descriptor's importance for the given activity as determined by SCR.  
2.6.2.c Modelability Index (MODI) 
The Modelability Index (MODI) estimates the likelihood of obtaining predictive QSAR 
models for a binary data set of compounds.44 MODI is defined as a weighted ratio of the number 
of nearest-neighbor pairs of compounds in descriptor space with the same activity class versus the 
total number of pairs. MODI threshold of 0.65 was previously found to separate the modelable 
from non-modelable data sets. MODI was calculated for both training sets to evaluate the 
feasibility of developing models with high predictive power for the training sets. 
2.6.2.d QSAR modeling 
Binary classification (active vs. inactive) QSAR models were developed and rigorously 
validated according to the best practices of QSAR modeling.9 Models utilized a combination of 
MNA and QNA descriptors85,86 and RBF-SCR87 as the machine-learning algorithm. All models 
were validated using five-fold external cross validation;9,73 Y-randomization88 and applicability 
domain (AD)43 were utilized for each QSAR model. Models were statistically evaluated according 
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to sensitivity (SE), specificity (SP), correct classification rate (CCR), positive predictive value 
(PPV), and negative predictive value (NPV), see the equations 1-5, respectively.  
SE =  
TP
TP+FN
   (1) 
SP =  
TN
TN+FP
  (2) 
CCR =  
SE+SP
2
  (3) 
PPV =  
TP
TP+FP
  (4) 
NPV =  
TN
TN+FN
  (5) 
Here, TP and TN represent the number of true positives (correct classifications of actives), 
and true negatives (correct classifications of inactives), respectively; whereas, FP and FN represent 
the number of false positives (incorrect classifications of actives) and false negatives (incorrect 
classifications of inactives), respectively. Models were deemed acceptable for virtual screening if 
and only if the CCR, SE, SP, PPV, and NPV were above 0.60, and no associated Y-randomized 
model had a CCR above 0.60.  
2.6.2.e Virtual screening 
A set of 169 compounds with pyrimido-diazepine scaffolds (Figure 2.2) considered 
synthetically feasible and possibly viable as DCLK1 inhibitors were used for prediction and 
prioritization. As above, the 2D structures were processed following the same curation protocols.37 
Consensus prediction was utilized, meaning that for a compound to be considered a “hit”, it must 
be within the applicability domain of each model and be predicted as “active” by both.  
2.6.2.f Matched Molecular Pair Analysis 
The KNIME implementation of the Hussain and Rea algorithm for identifying Match 
Molecular Pairs (MMPs) was utilized.89 The number of cuts to acyclic single bonds was set to 1, 
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and the maximum number of heavy atom changes was set to 6 to allow for the addition of six-
membered rings.  
2.6.2.g Molecular Docking 
The lowest energy configurations at pH 7 for the eleven experimentally validated 
compounds, as well as compounds in the training sets, were generated with the Ligand Preparation 
application (Schrödinger Release 2016-4: LigPrep, Schrödinger, LLC, New York, NY, 2016). 
Next, the crystal structure of DCLK1 (PBD: 5JZN)57 was downloaded from the Protein Databank 
(http://www.rcsb.org/pdb/home/home.do)90 and prepared for docking as follows. Briefly, bond 
orders were assigned, hydrogen atoms were added, selenomethionine residues were converted to 
methionines, and missing side chains were filled with the Prime application (Schrödinger Release 
2016-4: Prime, Schrödinger, LLC, New York, NY, 2016). The protein grid for docking was set by 
selecting the center of the cocrystal ligand in the PDB structure57. The Glide application was used 
for docking of all compounds into DCLK1 (Schrödinger Release 2016-4: Glide, Schrödinger, 
LLC, New York, NY, 2016). Flexible ligand sampling was allowed with the XP (extra precision) 
scoring function.91  
2.6.3 Experimental Methods 
2.6.3a DCLK1 Plasmid Construction 
The DNA construct consisting of N-terminally 6-His tagged human DCLK1 residues 
G351-H689 was obtained from Ana Clara Redondo of the Structural Genomics Consortium at the 
University of Oxford. The plasmid was co-transformed with lambda phosphatase under 
chloramphenicol selection into BL21 DE3 E.coli cells. 
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2.6.3b DCLK1 Protein Purification 
 
Protein expression was induced with 0.6 mM IPTG and expression was allowed to continue 
for ~10 hours at 18 °C. Bacteria were harvested by centrifugation and resuspended in Lysis buffer 
with protease inhibitors (1 mM Benzamidine and 1 mM PMSF). Lysis was performed by passing 
3 times through a homogenizer. Lysate was centrifuged at 20K for 1 hour, and the supernatant was 
filtered through a 0.2 micron membrane. Protein was captured using Nickle-NTA resin and eluted 
with imidazole. Eluate was concentrated to 2 mL and passed over a Superdex S200 column. The 
Lysis buffer was composed of 50mM Hepes (pH 7.8), 350 mM NaCl, 20 mM imidazole, and 5% 
glycerol. The first wash was the same as the Lysis buffer; the second was the same as Lysis buffer 
but with 25 mM Imidazole; the elution was the same as Lysis buffer but with 300 mM Imidazole. 
The S200 gel filtration buffer was composed of 10mM Hepes (pH 7.8), 700 mM NaCl, 1 mM 
MgCl2, and 5% glycerol.  
2.6.3c DCLK1 Mobility Shift Assay  
 
DCLK1 kinase activity was measured in vitro using an electrophoretic mobility shift assay. 
The reaction was assembled in a 384-well plate in a total volume of 20 μl. The reaction comprised 
30 nM recombinant DCLK1, one DCLK1 inhibitor or DMSO, 100 μM ATP  and 1 μM FAM-
labeled peptide substrate (peptide 12: 5-FAM-KKLRRTLSVA-COOH)  in a buffer (100 mM 
HEPES pH 7.5, 0.003% Brij-35, 0.004% Tween-20, 10 mM MgCl2, and 2 mM DTT). DCLK1 
inhibitors were dispensed using a Labcyte Echo liquid handler. The reaction was incubated at room 
temperature for two hours and quenched by addition of 40 μL of termination buffer (100 mM 
HEPES pH 7.3, 0.015% Brij-35, 0.1% CR-3, 1 x CR-8, and 40 mM EDTA). Substrate and product 
peptides present in each sample were electrophoretically separated and detected using 12-channel 
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LabChip3000 microfluidic capillary electrophoresis instrument (Caliper Life Sciences). The 
change in the relative fluorescence intensities of substrate and product peaks (reflecting enzyme 
activity) was measured. Capillary electrophoregrams were analyzed using HTS Well Analyzer 
software (Caliper Life Sciences). The kinase activity in each sample was determined as the 
product-to-sum ratio (PSR): P / (S + P), where P is the peak height of the product peptide and S is 
the peak height of the substrate peptide. Negative control samples (DMSO in the absence of 
inhibitor) and positive control samples (100% inhibition, a tested DCLK1 inhibitor) were 
assembled in replicates and were used to calculate percent inhibition values for each compound at 
each concentration. Percent inhibition (%Inhibition) was determined using equation 6: 
 (6) 
where PSRinh is the product-sum ratio in the presence of inhibitor, PSR0% is the average product-
sum ration in the absence of inhibitor and PSR100% is the average product-sum ratio in 100%-
inhibition control samples. The DCLK1 candidate inhibitors were tested in 8-point dose-response 
format on each assay plate. The IC50 values were determined by fitting the inhibition curves by 
an eight dose-response model using GraphPad Prism 7 software. 
 
2.6.4 Kinase Selectivity  
 
Kinome-wide profiling in the KiNativ assay was used to assess kinase promiscuity of 
potent DCLK1 inhibitors. 84 Compounds were screened against at least 239 kinases at 10 μM, and 
a single percent inhibition value was recorded. PC3 and HeLa cells were used, as well as multiple 
labeling sites. 
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For each compound, the selectivity index (SI) was assessed at thresholds of 65% and 90% 
kinase inhibition, i.e., SI(65) and SI(90). The SI was then computed according to equation 7: 
        𝑆𝐼(90) = 100 ∗  
𝑁ℎ𝑖𝑡𝑠
𝑁𝑡𝑜𝑡𝑎𝑙
                  (7) 
In this equation, SI(90) is the selectivity index at 90% inhibition, Nhits is the number of 
kinases inhibited by the compound at ≥ 90%, and Ntotal is the total of kinases against which the 
compound was screened. Likewise, SI(65) is the selectivity index at 65% inhibition.   
2.7 ASSOCIATED CONTENT 
Supporting Information. Supplementary Files and Tables for Chapter 2 are available at 
https://scapuzzi.web.unc.edu/free-downloads/ 
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CHAPTER 3: PHANTOM PAINS: A PUBCHEM-WIDE ANALYSIS OF PAN-ASSAY 
INTERFERENCE COMPOUNDS2 
3.2 INTRODUCTION 
The scientific community is in the grips of the data reproducibility crisis, highlighted by 
Nature’s “Challenges in Irreproducible Research” initiative.92,93 Oftentimes in drug discovery, 
compounds active in primary biological screens show no activity in follow-up studies.94–96 The 
measured effect of false positives may be due to various compound and assay liabilities including 
those that interfere with the assay detection technology such as auto-fluorescence, hydrogen 
peroxide production, metal chelation, chemical aggregation, etc.24,93–96  
We categorize compound and assay liabilities, as Type 1 and Type 2 behavior, respectively. 
Type 1 behavior is characterized by compounds that affect target activity by an undesirable 
mechanism of action (MoA).97 An example of Type 1 behavior is target engagement by colloidal 
aggregation.  The formation of compound aggregates is considered an undesirable MOA since 
these aggregates, not an individual compound, modulate the target and thus constitutes artefactual 
activity. Type 2 behavior is characterized by an assay result that gives a spurious measurement of 
compound activity against the target. Examples of Type 2 behavior include singlet oxygen 
quenching in the AlphaScreen assay platform or inhibition of reporter enzymes by screened 
compounds. Since the assay itself gives rise to artefacts, Type 2 behavior can be summarized as 
“assay interference.”  
                                                          
2 This chapter previously appeared as an article in the Journal of Medicinal Chemistry. The original citation is as 
follows: Capuzzi, S. J., Muratov, E. N., and Tropsha, A. “Phantom PAINS: Problems with the Utility of Alerts for P an- 
A ssay IN terference Compound S”. J. Chem. Inf. Model. (February, 2017) 57, 417–427. 
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Although assay interference can typically be determined by running orthogonal assays that 
probe activity with auxiliary readout technologies, in silico methods are sought to quickly (and 
without cost) identify compounds whose “activities” are attributable to interference. The most 
popular and promulgated computational tool to flag, and often triage, compounds that interfere 
with the bioactivity detection technology are so-called Pan-Assay INterference CompoundS 
(PAINS) filters.24  
PAINS filters are composed of 480 “alerts”, i.e., substructural features frequently found in 
PAINS.24  These alerts are computationally mapped and matched onto full compound structures 
to flag for potential liabilities.24 In essence, PAINS alerts are simple binary (yes or no) models that 
attempt to forecast assay interference propensity by classifying compounds as PAINS (have alerts) 
or non-PAINS (lack alerts).  Like other types of models, PAINS alerts were derived from a training 
set. This training set consisted of 7900 compounds tested in six AlphaScreen assays.24 Similarly, 
like other types of models, PAINS alerts, to be considered reliable, must be validated with external 
data and be constrained by a defined applicability domain.98   
During their original development, however, PAINS alerts were not validated using 
external data, i.e., the predictive power of the alerts to identify compounds that interference with 
the assay detection technology was not quantified.24 Moreover, the applicability domain of PAINS 
alerts has not been appropriately addressed in the published literature. This lack of a defined 
applicability domain has led to use of alerts beyond the original chemical space of the training set 
(Type 1 behavior) and beyond the AlphaScreen assay platform (Type 2 behavior). 
Despite these concerns, the concept of PAINS alerts (filters) has gained much attention, 
many supporters, and prompted many follow-up publications.99–101 Several web-based 
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applications relying on the original work by Baell and Holloway24 have been developed to flag 
and filter compounds with PAINS alerts;102,103 chemical databases, such as ZINC 
(http://zinc15.docking.org/) and ChEMBL (https://www.ebi.ac.uk/chembl/), also flag compounds 
containing PAINS alerts. On the scientific blogosphere, publications reporting compounds flagged 
with PAINS alerts as viable hits have been publicly ridiculed in a practice known as “PAINS-
Shaming.”104 
The wide acceptance of the PAINS concept by the scientific community and the availability 
of PAINS filters have made it common for researchers to triage virtual screening hits flagged with 
these alerts prior to experimental validation.105 Similarly, lead compounds resulting from 
experimental screening campaigns have typically been de-prioritized for follow-up studies if they 
contained PAINS alerts.106 Furthermore, scientific journals have begun to recommend that all hit 
compounds, virtual or otherwise, should be passed through one of the publicly available PAINS 
filters before the manuscript is considered for publication. For instance, the ACS Journal of 
Medicinal Chemistry requires that “active compounds from any source must be examined for 
known classes of assay interference compounds”.107 The authors are asked to “provide firm 
experimental evidence in at least two different assays that reported compounds with potential 
PAINS liability are specifically active and their apparent activity is not an artifact”.107 Thus, 
compounds with potential PAINS liability as those flagged with PAINS alerts.  
Amidst the generally wide acceptance of PAINS, there have been a few voices cautioning 
about the overarching utility of the alerts. Several authors have noted that the application of these 
alerts could discard viable drug candidates because such alerts have actually been found in 
approved drugs.108,109 More substantial criticism of PAINS alerts has emerged as well on internet 
forums (but not in peer-reviewed publications).  Aware of these concerns, in the course of our own 
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recent virtual screening investigations, we re-examined the original study6 from which the 480 
PAINS alerts were derived. We noticed that the study6 employed a relatively small (93K 
compounds) and proprietary library (complete chemical structures were not released) tested for 
one type of activity (protein-protein interaction inhibition) in just six HTS campaigns (three out of 
six targets were kept confidential) using a single detection technology (AlphaScreenTM).  
Though considerable effort was made to divulge as much information as possible, due to 
the proprietary nature of the original study and unavailability of the chemical library explored 
therein, the detection of PAINS and the derivation alerts could not be fully and independently 
reproduced. That being said, upon further inspection of the 92 pages of Supplemental 
Information24, we observed that more than half of the PAINS alerts were derived from one or two 
compounds only (Figure 3.1), with 68% (328 out of the 480 alerts) found in four or fewer 
compounds only, and more than 30% (190 PAINS alerts) found in one compound only showing 
“pan-assay” activity (Figure 3.1; Table S1). This preliminary analysis lead us to hypothesize that 
the majority of these alerts may have limited extrapolative power due to the constrained 
applicability domain.    
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Figure 3.1. Probing the extrapolative power of PAINS alerts. A histogram showing the 
distribution of the number of PAINS alerts (amounting to 480 total) as the function of the number 
of compounds used to derive each alert. Note that 190 PAINS alerts were derived from one 
representative compound only whereas only 18 PAINS alerts were derived from samples including 
more than 100 compounds per alert. 
Given the aforementioned limited applicability domain of PAINS alerts, we decided to 
probe into the “pan-assay” activity of PAINS and the reliability of PAINS alerts by analyzing 
publicly available data on extensively assayed compounds. To this end, we have (i) assessed the 
robustness of PAINS alerts at flagging frequent hitters among compounds assayed using the 
AlphaScreenTM technology as reported in PubChem; (ii) scanned PubChem to investigate the level 
of “pan-assay” activity of compounds with and without PAINS alerts; (iii) examined the frequency 
of PAINS alerts in extensively assayed, yet consistently inactive compounds known as “Dark 
Chemical Matter”110; and (iv) profiled the PubChem-wide activity of FDA-approved drugs with 
and without PAINS alerts. Overall, using publicly available data, this study sought to evaluate the 
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PAINS concept in general, with an additional focus on specific PAINS alerts established in the 
original investigation24, in order to provide both researchers and journal editors with insight into 
the utility of PAINS alerts as they currently stand.   
3.3 RESULTS AND DISCUSSION 
3.3.1 Detection of PAINS in chemical libraries tested with the AlphaScreenTM Technology 
We have identified six PubChem assays that measure protein-protein interaction (PPI) 
inhibition using AlphaScreenTM, i.e., the same type of activity and the same technology employed 
in the original study.6 The study design is shown in Figure 3.2. The six originally studied assays 
were run at the relatively high compound concentration of 25-50 μM in primary screens, which 
may account for the high rate of interference, and two of the assays used hexa-his/Ni anchors.24 
We have chosen these six PubChem assays, similar to a study by Schorpp et. al111, in order to 
assess the robustness of PAINS alerts to flag frequent hitters across a similar, but not identical, 
series of assays.  It should be noted that the anchorage and screening concentrations reported in 
PubChem were different from original study.  However, current PAINS filters look solely for the 
presence of specific functional groups in assayed chemicals regardless of the assay conditions; 
thus, the difference in these conditions does not invalidate the use of PAINS alerts in this 
investigation.  
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Figure 3. 2. Study design for examining compounds in PubChem tested with AlphaScreenTM 
assay technology. Six assays targeting PPIs and using AlphaScreenTM were identified in 
PubChem. Only those compounds that were tested in all six assays were considered. Compounds 
were binned into two categories according to the number of active calls. Compounds in each 
category were then queried for PAINS alerts. The PubChem-wide bioassay activity of all 
compounds was then investigated.  
 
As many as 153,339 unique compounds were found in PubChem to have been tested across 
all six assays (Table S2). Activity calls for each compound (Active, Inactive, and Inconclusive) 
were recorded as defined by the assay depositor. Compounds were then binned into two categories: 
“Frequent Hitters” (active calls in at least 2 out of 6 assays) and “Infrequent Hitters” (active calls 
in 1 or 0 assays), which is the same threshold as established in the original study24. Both categories 
were first queried for the presence of PAINS substructural alerts using the SMARTS 
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implementation from PubChem Promiscuity25, then confirmed using SYBYL Line Notation (SLN) 
implementation from FAF-Drugs3102. Four categories arose: “Frequent Hitters - PAINS” (FH-
PAINS), “Frequent Hitters – No PAINS” (FH-NoPAINS), “Infrequent Hitters - PAINS” (IH-
PAINS), and “Infrequent Hitters- No PAINS” (IH-NoPAINS). There was a concordance of 
~99.9% between the SMARTS and SLN implementations for flagging compounds with PAINS 
alerts (Table S3). The enrichment value (EV), which was previously defined24 as the percentage 
of compounds active in at least two of the six assays relative to the number of compounds that 
displayed no activity across all six assays, was calculated to compare FH-PAINS vs. IH-PAINS 
(Table S4 and S5).  
The results of our analysis are shown in Table 3.1. There were 902 compounds in the 
“Frequent Hitters” category, and 208 of these only (23%) contained PAINS substructural alerts 
(FH-PAINS). The remaining 694 “Frequent Hitters” lacked any PAINS alerts (FH-NoPAINS). For 
the “Infrequent Hitters”, 146,224 (96%) compounds lacked PAINS alerts (IH-NoPAINS), but 
6,413 compounds (4%) still contained the alerts (IH-PAINS). Comparing the numbers of IH-
PAINS and FH-PAINS leads to the apparent conclusion that, for this series of assays, the majority 
of compounds containing PAINS alerts (97%) were actually infrequent hitters.   
 
 
 
 
Table 3.1. Lack of pan-assay activity for compounds with PAINS alerts in PubChem. The 
average fraction of activity calls for PAINS and non-PAINS (defined as containing or lacking 
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PAINS alerts, respectively) across both detection technology-specific assays and all assays in 
PubChem. The average number of assays in which the compounds were tested are shown in 
parentheses.  
Compound Categories Ncompounds  Luciferase β-lactamase Fluorescence All Assays 
FH-PAINS* 208 12% (93) 4% (9) 7% (312) 10% (546) 
FH-NoPAINS* 694 6% (95) 2% (9) 3% (320) 5% (550) 
IH-PAINS* 6,413 3% (93) 1% (10) 2% (323) 2% (550) 
IH-NoPAINS* 21,500 1.5% (95) 0.5% (9) 1% (326) 1% (555) 
Random-PAINS** 14,611 3% (95) 1% (12) 2% (329) 3% (562) 
Random-NoPAINS** 58,722 2% (93) 0.6% (13) 0.8% (321) 1% (550) 
Drugs-PAINS** 
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9% (71) 
 
7% (40) 
 
6% (223) 
 
24% (602) 
 
Drug-NoPAINS** 1,373 5% (59) 5% (33) 3% (183) 15% (458) 
*Defined by the compound profile in PPI assays utilizing AlphaScreenTM ; 
**Defined by presence or absence of PAINS alerts. 
 
The enrichment value calculated for PAINS-containing compounds (FH-PAINS and IH-
PAINS) was only 3.5% (Table  S4 and S5). Furthermore, if IH-PAINS that were active in one 
assay only were taken into consideration, the overall EV fell to 3.2% (Tables S4 and S5). The 
analysis of this series of assays indicates that PAINS alerts are found much more frequently in 
non-promiscuous compounds. 
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To probe whether or not this observation is only limited to assays related to PPIs using 
AlphaScreenTM, we investigated the PubChem-wide bioassay activity of the same compounds. 
Given that IH-NoPAINS constituted the overwhelming majority of all compounds discussed above 
(146,224 compounds), the PubChem-wide activity of all IH-NoPAINS was not evaluated due to 
computational constraints. Instead, a random subset of 21,500 IH-NoPAINS (Table S7) were 
evaluated; this number was selected to preserve approximately the same ratio of frequent to 
infrequent NoPAINS (1:3.5) as was observed for the PAINS (cf. Table 3.1). PubChem 
Promiscuity25,112 was used to retrieve the activity calls for all four aforementioned categories of 
compounds (FH-PAINS, IH-PAINS, FH-NoPAINS, and IH-NoPAINS) tested in luciferase-, beta-
lactamase-, and fluorescence-based assays (See Tables S4-S7). Lastly, we assessed activity calls 
across all bioassays in PubChem irrespective of the detection technology (Table 3.1).  
We found that across all assays, including those that have been reported as particularly 
susceptible to interference,96 FH-PAINS were active in more assays than FH-NoPAINS; however, 
IH-PAINS were active in fewer assays than FH-PAINS (Table 3.1). The reduced activity of IH-
PAINS in the AlphaScreenTM assays, therefore, is not limited to this detection technology, as it can 
be observed over all reported assays in PubChem. Also, both categories of frequent hitters in 
AlphaScreenTM (FH-PAINS and FH-NoPAINS) showed greater PubChem-wide activity than 
infrequent hitters containing PAINS alerts (IH-PAINS). Therefore, the broader activity spectrum of 
these frequent hitters is independent of the presence or absence of any PAINS alerts, highlighting 
the importance of considering molecular entities as a whole rather than chemical fragments when 
trying to derive any structural rules governing assay promiscuity.   
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3.3.2 Analysis of PAINS alerts in chemical libraries tested with the AlphaScreenTM 
Technology 
The specific alerts found in the above FH-PAINS and IH-PAINS categories were then 
investigated on an individual basis. In total, 163 individual PAINS alert types were observed in 
compounds among the two categories (Table S8). It should be noted that multiple PAINS alerts 
could be present within a single compound (Figure 3.3). 
 
Figure 3. 3. Compounds with multiple PAINS alerts. Two representative compounds from the 
IH-PAINS and FH-PAINS categories that contain multiple PAINS alerts.   
For the 208 FH-PAINS compounds, 41 individual PAINS alerts were detected (Table S8). 
Of these 41 alerts, only 7 alerts, i.e., quinone_A(370), mannich_A(296), ene_six_het_A(483), 
anil_di_alk_B(251), anil_di_alk_A(478), ene_one_hal(17), and imine_one_A(321), were found in 
more than 10 FH-PAINS compounds. The remaining 34 PAINS alerts were present in 10 or less 
FH-PAINS compounds.   
For the 6,314 IH-PAINS compounds, 162 individual PAINS alerts were detected (Table 
S8). Of these 162 alerts, 57 alerts were found in more than 10 IH-PAINS compounds. Moreover, 
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15 of these alerts were found in more than 100 IH-PAINS compounds. The anil_di_alk_A(478) 
alert, for example, appeared in 1,083 IH-PAINS compounds.  
Next, the PAINS alerts that were present in both the FH-PAINS and IH-PAINS were 
analyzed. Within these two categories, 40 individual PAINS alerts were shared, roughly ~25% of 
all observed alerts. Only one alert, i.e., anil_no_alk_A(1), was unique to FH-PAINS (Table S8); 
however, only 1 compound possessed this alert, which is consistent with the limited sample size 
(1 compound) used to derive this alert (cf. Figure 3.1). Similarly, 122 alerts were unique to IH-
PAINS (Table S8). For this series of assays, ~75% PAINS alerts present in the PubChem library 
analyzed herein (122 out of 163) were found only in the Infrequent Hitters.    
The enrichment value (EV), defined as percentage of compounds active in at least two of 
the six assays relative to the number of compounds active in 1 or 0 assays, was calculated for each 
of 40 shared PAINS alerts (Table 3.2).  Only 6 alerts showed EVs greater or equal to 25%. 
However, 4 of these 6 alerts had less than 10 representative compounds. Therefore, 2 alerts, i.e., 
quinone_A(370) and quinone_D(2), were found in 10 or more compounds and had an EV greater 
or equal to 25%. The remaining 34 shared alerts had EVs less than 25%, and 32 of these 34 alerts 
had more than 10 representative compounds.  Indeed, 6 shared alerts had EVs less than 1.0% 
despite being present in more than 100 compounds. For this series of assays, the vast majority of 
PAINS alerts were found among the Infrequent Hitters (IH-PAINS) at much higher frequencies. 
The full analysis of all 40 shared alerts, including representative compound sizes and EVs, can be 
found in Table 3.2.   
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Table 3.2. PAINS enrichment in six PubChem assays employing AlphaScreenTM. Forty alerts 
were present in both FH-PAINS and IH-PAINS. Two alerts showed EVs greater or equal to 25% 
and were found in 10 or more total compounds. Six alerts had EVs below 1.0%.   
PAINS Alert Substructure24 NFH-PAINS NIH-PAINS NPAINS EV, % 
quinone_B(5) 
 
3 1 4 300.0 
imine_ene_A(5) 
 3 2 5 150.0 
het_65_Db(5) 
 
4 3 7 133.3 
ene_rhod_J(3) 
 
1 3 4 33.3 
quinone_A(370) 
 
47 160 207 29.4 
quinone_D(2) 
 
9 36 45 25.0 
dyes5A(27) 
 
1 
5 6 20.0 
anthranil_one_A(38) 
 
3 
16 19 18.8 
imine_one_sixes(27) 
 
3 
16 19 18.8 
het_pyridiniums_A(39) 
 
5 
29 34 17.2 
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anil_alk_ene(51) 
 
2 
12 14 16.7 
thio_urea_D(8) 
 
1 
6 7 16.7 
ene_one_hal(17) 
 
14 
89 103 15.7 
anil_di_alk_B(251) 
 
16 
116 132 13.8 
ene_five_het_A(201) 
 
7 
51 58 13.7 
het_thio_5_imine_A(1) 
 
1 
9 10 11.1 
rhod_sat_A(33) 
 
4 
39 43 10.3 
dyes3A(19) 
 
1 
11 12 9.1 
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sulfonamide_B(41) 
 
2 
25 27 8.0 
azo_A(324)  9 
114 123 7.9 
mannich_A(296) 
 
36 
472 508 7.6 
anil_di_alk_F(14) 
 
1 
14 15 7.1 
imine_one_A(321) 
 
12 
215 227 5.6 
ene_one_ene_A(57) 
 
2 
40 42 5.0 
anil_no_alk(40) 
 
2 
48 50 4.2 
cyano_imine_A(37) 
 
1 
26 27 3.9 
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ene_six_het_A(483) 
 
18 556 574 3.2 
anil_di_alk_D(198) 
 
5 155 160 3.2 
imine_one_fives(89) 
 
1 38 39 2.6 
hzone_pipzn(79) 
 
2 87 89 2.3 
anil_di_alk_E(186) 
 
3 148 151 2.0 
thiophene_amino_Ab(40) 
 
1 71 72 1.4 
catechol_A(92) 
 
1 75 76 1.3 
anil_di_alk_A(478) 
 
14 1083 1097 1.3 
imine_one_isatin(189) 
 
1 111 112 0.90 
pyrrole_A(118) 
 
2 269 271 0.74 
ene_rhod_A(235) 
 
4 593 597 0.67 
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anil_di_alk_C(246) 
 
4 641 645 0.62 
ene_five_het_B(90) 
 
1 161 162 0.62 
indol_3yl_alk(461) 
 
1 354 355 0.28 
 
3.3.3 Random PAINS in PubChem 
We also evaluated the PubChem-wide activity of compounds tested in at least 25 separate 
bioassays based only on the presence or absence of 480 originally established PAINS alerts, i.e., 
irrespective of any perceived promiscuity across a selected series of specific assays. Randomly 
selected compounds that were evaluated in the previous section were excluded. The resultant 
dataset contained 73,333 individual compounds. The structures of these compounds were 
searched for PAINS alerts (described above) and binned into two categories: Random-PAINS 
(14,611 compounds) and Random-NoPAINS (58,722 compounds). We compared these two 
categories following the same protocol as described in the previous section (Table 3.1). The 
average pan-assay activity of Random-PAINS was just 3%, compared to an average of 1% for 
Random-NoPAINS (Table 3.1), i.e., Random-PAINS were marginally more active than 
Random-NoPAINS. Additionally, of the 14,611 Random-PAINS only 752 compounds (5% of 
the total) showed activity in at least 10% of all assays. Of the remaining 13,859 Random-PAINS 
(95%) that were active in less than 10% of all assays, 1,146 had no activity at all, despite being 
tested in an average of 443 assays (Table S9 and S10). These results indicate that the mere 
presence of a PAINS substructure does not give rise to any observed pan-assay activity, nor any 
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marked interference trends in luciferase-, beta-lactamase-, or fluorescence-based assays. In fact, 
only two PAINS alert containing compounds, tanespimycin and dihydrexidine, were active in 
more than 50% of the assays (Figure 3.4). In total 202 PAINS alerts were found among the 
Random-PAINS category, A PubChem-wide analysis of alerts in random PAINS is described in 
the Global Analysis of PAINS Alerts Section. 
  
Figure 3. 4. Random-PAINS displaying pan-assay activity. Tanespimycin  
and dihydrexidine are active in 85% and 50% of all assays in PubChem, respectively.   
 
 
3.3.4 Analysis of PAINS Alerts in Dark Chemical Matter 
Following the observation that Random-PAINS can be consistently inactive across a large 
number of assays, we probed the so-called Dark Chemical Matter (DCM)110 for the presence of 
PAINS alerts. DCM was defined by Wasserman et al.110 as compounds that hav 
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e not yet shown any activity when tested in a minimum of 100 assays. The complete dataset of 
139,352 DCM compounds, i.e. 128,997 PubChem and 10,355 Novartis DCM compounds, was 
downloaded from the Supplementary Information of the respective study.110  
The dataset was examined with FAF3-Drugs102, and 3,570 DCM compounds containing 
PAINS substructures were found, encompassing 109 of the 480 original PAINS alerts24 (Table 
S11). Of these 109 PAINS alerts, 30 alerts were found in more than 10 compounds and 10 alerts 
were present in 100 or more compounds (Table 3.3).  This analysis shows that even extensively 
assayed compounds containing PAINS alerts may be consistently inactive.  
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Table 3.3. PAINS alerts enriched in Dark Chemical Matter.  
Ten alerts are present in 100 or more in Dark Chemical Matter 
compounds (NDCM).  
PAINS Alert Substructure6 NDCM 
anil_di_alk_A(478) 
 
902 
anil_di_alk_C(246) 
 
492 
indol_3yl_alk(461) 
 
343 
ene_six_het_A(483) 
 
256 
mannich_A(296) 
 
212 
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imine_one_A(321) 
 
193 
anil_di_alk_D(198) 
 
184 
anil_di_alk_E(186) 
 
164 
ene_rhod_A(235) 
 
116 
pyrrole_A(118) 
 
100 
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3.3.5 Global Analysis of PAINS Alerts 
In this study, a total of 24,802 PAINS compounds were analyzed (208 FH-PAINS, 6413 
IH-PAINS, 14611 Random-PAINS, and 3570 DCM-PAINS) covering 220 specific PAINS alert 
types, which is ~ 46% of the original PAINS alerts.24  In order to determine if specific PAINS 
alerts correspond to compounds with elevated assay promiscuity, we performed a global analysis 
of the PubChem-wide activity of all PAINS compounds investigated herein (Tables 3.6-3.9). 
Since there is no agreed upon threshold of “pan-assay” activity, we selected assay activity of at 
least 10% as an arbitrary classifier.  
Of these 220 PAINS alert types, 32 alerts had greater than 10% assay activity in either all 
assays, luciferase-, beta-lactamase-, or fluorescence-based assays (Table 3.4). However, only 12 
of these alerts were present in more than 10 compounds (Table 3.5). It should be noted, however, 
that 6 of these alerts can also be found in DCM.   
On the other hand, 176 (~80%) of the total PAINS alerts analyzed (220) were active in less 
than 10% of all investigated assays and technologies, and 88 alerts were present in DCM (Tables 
3.6 and 3.7). Eighty-four (84) of 176 alerts were present in more than 10 compounds (Table 3.6). 
Interestingly, 6 of these alerts were found in more than 1,000 compounds (Table 3.6). Finally, 12 
alerts were found exclusively in DCM-PAINS (Table 3.8).  Eleven of these alerts were found in 
less than 10 compounds, while one alert, i.e., hzone_phenol_B(215), was present in exactly 10 
compounds. 
There are 16 PAINS alerts that were derived from more than 150 compounds (cf. Fig. 
3.1). Of all 480 alerts, these 16 alerts were created from the most underlying data in the original 
study6. Given the prevalence and heightened promiscuity of compounds possessing these alerts 
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in the original study, we specifically investigated whether any compounds in our collection 
flagged by these 16 alerts display suspect assay trends (Table 3.9). Aside from hzone_phenol_A 
(479) and hzone_phenol_B(215), which were found exclusively in DCM, 14 of these 16 alerts 
were frequently assayed and abundantly present in the public collection. All 14 alerts displayed 
less than 10% activity in all PubChem assays despite being tested on average in more than 500 
assays each. Among these specific alerts, the quinone_A(370) alert demonstrated the highest 
activity in all assays (8.4%).   
Our findings using data in the public domain can be corroborated in part by other inquiries 
into the nature of promiscuous compounds. For instance, while attempting to use PAINS alerts to 
fill gaps in Eli Lilly’s promiscuity filters, Bruns and Watson observed that “PAINS queries 
matched 286 promiscuous compounds that passed the Lilly rules, compared to 3986 in the non-
promiscuous set, for an enrichment factor of 4.0”113. Furthermore, they noted that “although 67 
PAINS queries matched at least one promiscuous compound, only nine queries matched at least 
five promiscuous compounds and had an enrichment of at least 5.”113 These findings are consistent 
with our observations that PAINS alerts in public data frequently flag non-promiscuous 
compounds or are manifested in only a small number of promiscuous compounds. 
On the other hand, another study on frequent hitter behavior by researchers at AstraZeneca 
showed elevated “Frequent-hitter Incidence %” for 10 out of 15 PAINS alerts.114  Although the 
authors state that their “corporate data largely confirm previous observations of the PAINS 
classes”, this study only investigated part of the first tier of the 480 PAINS alerts, i.e., the 15 out 
of 16 alerts derived from more than 150 compounds (cf. Figure 3.1), or ~3% of all alerts.114   As 
can be seen, in that study, one-third of the profiled alerts did not show elevated frequent-hitter 
behavior, which is, in part, aligned with our general observations (Tables 3.9).  
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3.3.6 PAINS Alerts in Drugs  
Other groups have noted that many drugs contain PAINS alerts,24,108,109 and several careful 
and keen analyses have centered around this phenomenon.115  It has also been observed that many 
of these PAINS alerts in drugs (but not all) map to poor ADMETox properties, such as quinone-
containing drugs.24 While this is an interesting observation, we view interference propensity and 
poor ADMETox properties as separate phenomena. Our group116 as well as others19 have also 
shown that a great majority of toxicity structural alerts, much akin to PAINS alerts, are overly 
sensitive and not predictive of actual in vitro or in vivo toxicity. Given that drug repurposing is 
currently widely used as a boon to traditional drug discovery117,118, we profiled the PubChem-wide 
bioassay activity of drugs with and without PAINS alerts (Table S12).   
A list of 1,460 approved small-molecule drugs was compiled from Drugs@FDA 
(https://www.accessdata.fda.gov/scripts/cder/drugsatfda/). Structures for these drugs were 
searched for PAINS alerts.102,25,112 We identified 87 small-molecule approved drugs possessing 25 
individual PAINS alerts (Table S12). As observed in the preceding sections, Drugs-PAINS are 
more active than Drugs-NoPAINS, having activity in 24% and 15% of all bioassays in PubChem, 
respectively (Table S12). According to current filters25,102, 16 of these drugs possess quinone 
PAINS alerts. The promiscuity of quinone-containing drugs have been extensively discussed in 
the PAINS literature24,115 and is supported by our analysis (cf. Tables 3.2 and 3.4). For instance, 
the chemotherapeutic doxorubicin, which contains the quinone_A(370) alert, has been tested in 
more than 4,000 assays with active calls ~85% of the time.  
At the same time, however, the relationship between polypharmacology and PAINS has 
not yet been adequately explored. Many drugs show polypharmacological behavior and possibly 
derive their efficacy from interacting with multiple targets119. Indeed, a similar study on 
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promiscuity in extensively assayed compounds found that drugs are more promiscuous than 
bioactive compounds119, which is evidenced in our analysis as well (Table 3.1). Polypharmacology 
may well account for the increased activity of both Drugs-PAINS and Drugs-NoPAINS relative to 
the other categories (cf. Table 3.1). While the phenomena of assay interference and 
polypharmacology have rightfully been contrasted119, there is very real possibility that a compound 
may both possess PAINS alerts and display polypharmacological behavior. Given that PAINS-
containing drugs are now frequently used in drug repurposing screens, a larger discussion about 
the utility of PAINS alerts and polypharmacology should take place.  
3.3.7 Beyond PAINS Substructures  
PAINS concept has been widely accepted by many experienced medicinal chemists both 
in academia and the pharmaceutical industry.  Indeed, the original study from which the PAINS 
alerts were derived and the impetus behind it are an important step towards reproducibility and the 
appropriate use of resources in drug discovery. However, our findings based on the analysis of 
public data suggest that many compounds containing PAINS alerts do not actually show high assay 
promiscuity, leading to the conclusion that these alerts should not be blindly used, in the absence 
of orthogonal experimental assays, to deprioritize a compound.   
At the same time, it is undeniable that pan-assay interference compounds exist and care 
must be taken to avoid these compounds. Moreover, we recognize that true “PAINS” may be 
present in the data analyzed herein but have not been classified as such because the current alerts 
do not cover these compounds120. The issue of what constitutes a pan-assay interference 
compound thus remains unclear.  For example, in How to Triage PAINS-Full Research, Dahlin 
and Walters define PAINS as “compounds that are recognized by the substructure filters reported 
by the Baell and Holloway article.”120 By this definition, all alerts (filters) are treated equally, 
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regardless of the underlying data used to derive the alert or the actual promiscuity of flagged 
compounds.  Yet our analysis indicates that the identification of such compounds should not be 
restricted to substructures alone. Substructural alerts, PAINS or otherwise, do not take into 
consideration the whole molecular environment116, as illustrated by PAINS alerts manifesting in 
both promiscuous and frequently inactive compounds (DCM). Attempts should then be made to 
move beyond substructural or fragment-based alerts. For instance, Yang and coworkers in their 
“BadApple” algorithm have extended the identification of promiscuous compound to larger 
scaffolds.121  
In recent publications by Alves et al.122–124, quantitative structure-activity relationship 
(QSAR) models were used in conjunction with structural alerts for toxicity to dramatically improve 
the accuracy of prediction of multiple toxicity endpoints over alerts alone. The authors of the 
present study advocate the development of a similar approach for PAINS alerts.  Such publicly 
accessible models, if successful, could be employed even for proprietary compounds insofar as 
chemical descriptors of PAINS-containing compounds could be shared without divulging actual 
molecular structures (given the proprietary nature of most compounds used to derive and evaluate 
PAINS so far24,113,114). The challenge is to build externally predictive QSAR models capable of 
classifying PAINS versus non-PAINS compounds. Using such models, predictions of suspect 
compounds could be made, giving higher confidence in the utility of the alert and the nefarious 
nature of the compound. 
Meanwhile, the concept of PAINS alerts, at the very least, needs a re-defined set of “best 
practices”120 that covers the appropriate use of alerts, which may include cross-referencing the 
promiscuity profiles of structurally similar compounds or alert types in the public domain, 
annotation of particularly susceptible assays, targets, and conditions, pointers to the appropriate 
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controls, and a generally agreed upon definition of “pan-assay” activity. It would be of great value 
if a community-wide effort to screen and analyze a large set of commercially available compounds 
representing the all current PAINS alerts against multiple targets in various assays was performed 
by several independent groups.  
3.4. CONCLUSIONS 
It is imperative to establish target selectivity for any compound considered a viable 
chemical probe or drug candidate through rigorously acquired experimental data and meaningful 
SAR. Future studies may well establish some generalized approach for detecting frequent hitters 
engendered by assay interference. However, until such approaches are developed and rigorously 
validated across a large number of molecules, researchers should be cautioned about using the 
current PAINS alerts as reliable indicators of non-specific pan assay interference. Though it has 
been stated elsewhere that compounds flagged with PAINS alerts are not active in all assays or 
against all targets,24,120 our analysis provides systematic and data-driven support of this claim 
across a large series of compounds, alerts, and assays.  Our findings do demonstrate, with publicly 
available data at hand, that majority of the original PAINS alerts are not indicative of pan-assay 
compound promiscuity, that many compounds without PAINS alerts are as, if not more, 
promiscuous as those with the alerts, and that many compounds flagged by PAINS alerts show no 
activity.  It is of great importance that reviewers and journal editors request experimental proofs 
of selectivity, such as orthogonal experimental assays, for hit and lead compounds reported in 
scientific manuscripts. However, the results of this study strongly suggest that such requests should 
not be based solely on the results of PAINS filters.120    
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3.5 ASSOCIATED CONTENT 
Supporting Information. Supplementary Files and Tables in Chapter 3 are available at 
https://scapuzzi.web.unc.edu/free-downloads/ 
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CHAPTER 4: CHEMOTEXT: A PUBLICLY-AVAILABLE WEB SERVER FOR 
MINING DRUG-TARGET-DISEASE RELATIONSHIPS IN PUBMED3 
4.2 INTRODUCTION  
The fundamental goal of small molecule drug discovery is the identification of bioactive 
compounds for the treatment of disease125. Many modern drug discovery projects start with the 
discovery of novel targets and then progress in the direction of finding ligands of these targets that 
are expected to affect the disease. Bioactivity data from drug repurposing/discovery campaigns are 
increasingly available in public databases such as PubChem35,126 and ChEMBL127. At the same 
time, much information about the biological underpinnings of disease, i.e., effector proteins and 
pathways, as well as drug targets are stored primarily in the biomedical literature. Thus, 
biomedically relevant relationships between drugs, biological targets, and diseases, which we call 
the DTD triangle, can be identified through mining the published biomedical literature.128,129  
PubMed, the largest repository of published biomedical research, is a freely-accessible 
search engine maintained by the United States National Library of Medicine (NLM) at the National 
Institutes of Health (NIH)130.  PubMed can be used to retrieve scientific articles containing specific 
search terms that are stored in the Medline bibliographic database. PubMed can also return a list 
of Medical Subject Headings (MeSH), or so-called MeSH terms131. The purpose of these MeSH 
terms is to index and categorize published studies by the subject matters discussed therein. As 
                                                          
3 This chapter previously appeared as an article in the Journal of Medicinal Chemistry. The original citation is as 
follows: Capuzzi, S. J., et. al. “Chemotext: A Publicly Available Web Server for Mining Drug–Target–Disease 
Relationships in PubMed.” J. Chem. Inf. Model. (February, 2018) 58, 212–218. 
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most drugs, biological targets, and diseases discussed in biomedical literature are captured by 
associated MeSH terms, relationships between terms in the DTD triangle (represented by edges of 
the triangle with vertices representing MESH terms) can be established based on their frequent co-
occurrences within articles.   
Indeed, such considerations led to the development of the Chemotext approach,132 which 
focused on the extraction of MeSH terms describing “chemicals”, “targets”, and “diseases”, i.e., 
the components of the DTD triangle, that were found to frequently co-occur in abstracts of papers 
annotated in PubMed. These co-occurrences were regarded as an indication of plausible assertions 
linking drugs, targets and diseases. Furthermore, Chemotext was conceived as an extension of 
Swanson’s ABC paradigm132–134 wherein “A” terms are chemical (drug) - related MeSH terms, 
“B” terms are so-called “target” MeSH terms, i.e., proteins and pathways, and “C” terms are MeSH 
terms for diseases (Figure 4.1). The underlying hypothesis generation starts with the observation 
that the name of drug “A” co-occurs in the same articles as the name of target “B” while the name 
of disease “C” co-occurs in the same or additional articles with the same target “B”. Thus, if drug 
“A” and disease “C” have not been mentioned together in the same article, an “A-C” connection 
mediated though target “B” can be inferred. This analysis leads to the identification of a new 
possible therapeutic use of drug “A”. This reasoning protocol illustrates one of possible uses of 
Chemotext for drug repurposing, which has emerged in the past decade as a boon to traditional 
drug discovery.118,135  
Although efforts have been made to develop tools for text-mining of PubMed, such as 
“MeSHSim”,136 “pubmed.mineR”,137 and IBM-Watson,138 these current implementations are 
either available only as R-packages,136,137 which are not user-friendly, and/or proprietary.138 To 
this end, we have developed the publicly-available Chemotext Web server that mines published 
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literature in PubMed in the form of MeSH terms. The goal of Chemotext is to establish text-based 
drug-target-disease relationships, which, as we show herein, can be used to generate novel drug 
repurposing hypotheses or elucidate clinical outcomes pathways that mechanistically connect 
drugs and diseases via intermediary, target-mediated biological effects of drug action.  Similar to 
our Chembench Webportal,46 the Chemotext Web server is hosted by the Molecular Modeling 
Laboratory (MML) at the University of North Carolina – Chapel Hill and is freely-available at 
http://chemotext.mml.unc.edu/.  
 
Figure 4. 1. Swanson’s ABC paradigm used in Chemotext.  Chemical A is proposed to have an 
effect on Disease C since both terms are associated with Target B. Solid lines (edges) indicate an 
actual text-based relationship, while dashed lines (edges) indicate proposed connections. 
4.3 METHODS  
The Chemotext user interface is written in JavaScript with data retrieval through 
JQuery’s Asynchronous JavaScript and XML (AJAX) functionality.139  The data are stored in 
Neo4j, a graph database that uses nodes for articles and drug terminology. The server operates on 
Red Hat Linux and is hosted by the Longleaf computer cluster at UNC-Chapel Hill. MeSH term 
data were downloaded directly from the PubMed and Medline repository. Data were input into 
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Neo4j using Cypher to parse the MeSH XML and to create the article and term nodes and 
relationships. Cypher queries allow for Neo4j to return sets of MeSH terms and article counts 
from the input term’s article relationships.  
Data for calendar year 2016 were retrieved from the MEDLINE/PubMed Baseline 
Repository (MBR) in June 2017. Data are available at https://mbr.nlm.nih.gov/Downloads.shtml.  
Currently, the Chemotext database contains 19,282,732 articles and 78,758,882 connections 
between terms. Chemotext is currently fully functional only with the Google Chrome web 
browser on both PC and MAC operating systems.  
4.4 CHEMOTEXT ENVIRONMENT  
Chemotext generates text-based relationships via four modules described below: Find 
Connected Terms, Find Shared Terms, Path Search, and Find Articles. Within each module, 
there is a query bar that possesses the full dictionary of MeSH terms with an auto-complete 
function to facilitate searching. Each module can be executed separately or as part of a larger 
study design. On its homepage, Chemotext possesses direct link to the Medical Subject Headings 
search engine in order to facilitate the identification of correct MeSH terms for querying. 
4.4.1 Find Connected Terms 
In this module, every MeSH term that occurs in the same article as a query term is 
returned, and the total number of co-occurring terms and the associated article counts are 
reported. A schema of this module is presented in Figure 4.2A. To illustrate how this module is 
used, if “Kinase” is queried, 7 821 unique co-occurring MeSH terms are returned (Figure 4.2B), 
such as “Enzyme Inhibitors,” an A term with 333 article co-occurrences, and “Neoplasms”, a C 
term with 151 article co-occurrences (Table S1).    
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The resultant terms are rank-ordered by the number of unique articles in which the term 
co-occurs with the query. Thus, the article count serves as a proxy for the strength of the 
association between terms in the A-B-C paradigm. For each co-occurring term, the user can click 
on the article count and view all of the associated article PubMed Identification (PMID) 
numbers. These PMIDs are linked to PubMed, allowing the user to access and review the 
article(s) in which the two terms are mentioned together.  
The full list of co-occurring terms can be filtered by MeSH term type, i.e, by “Chemical” 
terms, “Proteins-Pathways-Intermediaries-Other”, or by “Disease and Indication”, which 
correspond to A, B, and C terms, respectively (cf. Figure 4.1). Moreover, each MeSH term type 
(A, B, or C) has additional subtypes that facilitate further refinement of the co-occurring terms. 
For instance, Chemical (A) terms can be filtered by “Drug” terms, which allows the user to 
identify which FDA-approved drugs co-occur in the same articles as the query term. The full list 
of term subtypes for filtering is provided in the Supporting Information (Table S2). Aside from 
type, the co-occurring terms can be filtered by date of publication; thus, all terms appearing in 
articles published before or after a certain date can be retrieved.  
Users are able to download two CSV files. First is a file of the co-occurring terms and the 
associated article counts, while the second is a file of co-occurring terms, the article counts, and 
the explicit PMIDs.   
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A 
B 
Figure 4. 2. (A) Schema of the Find Connected Terms Module. A query term (Q) is input and 
all co-occurring A, B, C terms connections are established and putative connections are proposed. 
Solid lines indicate actual text-based co-occurrences, while dashed lines indicate proposed 
connections. It should be noted that Q can be either an A, B, or C term.  (B) Find Connected 
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Terms Module Output. All A, B, and C terms (7 821 total) that co-occur in the same articles as 
the query term “Kinase” are returned with the associated article counts. Resultant terms can be 
filtered by sub-terms and date, and the results and PMIDs can be downloaded.  
4.4.2 Find Shared Terms 
In this module, two query terms are input, and co-occurring terms and the article counts 
that are shared between the queries are returned. A schema of this module is presented in Figure 
4.3A. 
Thus, this type of search outputs the associated counts of co-occurrence for three 
instances: (i) when all three terms (query 1, query 2, and co-occurring term) are present in the 
same article, (ii) when the term co-occurs only in articles with query 1, and (iii) when the term 
co-occurs only in articles with query 2.  For example, when “Kinase” and “Neoplasm” are 
queried together in this module (Figure 4.3B), the term “Antineoplastic Agents” co-occurs in 36 
articles with both “Kinase” and “Neoplasm”, 106 articles with only “Kinase”, and 34 961 articles 
with only “Neoplasm” (Table S3).  It should be noted, however, that if a term co-occurs with 
only one of the queries, then this co-occurring term is not returned in this module, as it does not 
occur with the other query.  The term, therefore, is not shared between the two query terms.   
The resultant terms are rank-ordered by the number of unique articles in which all three 
terms co-occur. Since all three terms occur in the same article(s), these associations are 
considered the strongest.  
For each shared co-occurring term, the user can click on the article count and view all of 
the associated article PMID numbers when all three terms are present in the same article. As 
stated previously, these PMIDs are linked to PubMed. If for the case where the term co-occurs 
with query 1 and query 2, but are not necessarily present in the same articles, then the user can 
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obtain these PMIDs and links to articles in the “Find Connected Terms” module. The same 
previously described filters and downloadable files are available in this module.  
A 
B 
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Figure 4. 3. (A) Schema of the Find Shared Terms Module. Two query terms, Q1 and Q2, 
representing any pair of A, B, and C terms, are input, and all co-occurring A, B, and C terms shared 
between the query terms are established. (B) Find Connected Terms Module Output. Two query 
terms, “Kinase” and “Neoplasm”, are input, and all co-occurring A, B, and C terms shared between 
the query terms are established (5 672 shared terms). Resultant terms can be filtered by sub-terms 
and date, and the results and PMIDs can be downloaded. 
4.4.3 Path Search 
In this module, complete text-based A-B-C connections can be made through co-
occurring MeSH terms.  The name of this module – “Path Search” – indicates that these A-B-C 
connections can be established through several “paths”, i.e., through multiple intermediary terms 
or through a single intermediary term. A schema of this module is presented in Figure 4.4A. 
In the most complex and comprehensive path search, every possible A-B-C connection 
for a given query term can be established. For instance, if “Kinase” is queried and “Diseases and 
Indications” are chosen as the intermediary term, 1 242 unique MeSH terms are returned, 
representing 1 242 unique B-C connections. Examples of these unique B-C connections are as 
diverse as “Kinase-Neoplasms,” “Kinase-Gout,” and “Kinase-Leprosy.” Next, all 1 242 B-C 
connections can be queried for associated A-terms, thereby completing every possible A-B-C 
connection, i.e. DTD triangles. In this case, every chemical that can be associated with the B-
term “Kinase” as mediated through the 1 242 C-terms is identified.  
This path search can be simplified to identify more focused A-B-C connections through a 
single intermediary term. Using an above example, the single B-C connection of “Kinase-
Neoplasms” can be queried for all co-occurring “Chemical” A-terms, resulting in 9802 unique 
A-B-C connections mediated through the “Kinase-Neoplasms” nodes (Figure 4.4B). Of these 9 
802 unique A-B-C connection in this path search (Table S4), Chemotext retrieves 270 articles 
that establish the specific A-B-C connection of “Imatinib-Kinase-Neoplasms.”  This connection 
represents a known drug-target-disease relationship, as the tyrosine kinase inhibitor imatinib is 
115 
 
 
used to treat several cancers, including gastrointestinal stromal tumors (GIST) through the 
blockage of the receptor tyrosine kinase c-kit.140 In the Case Study, we will demonstrate that 
imatinib can also be repurposed as a treatment for asthma.   
In the Path Search module, the intermediary term type can either be the MeSH term type, 
i.e., “Disease and Indication”, “Proteins-Pathways-Intermediaries-Other”, “Chemical” terms, or 
the MeSH term subtypes, such as “Viruses”, “Enzymes and Co-Enzymes”, and “Heterocyclic 
Compounds”.  Regardless of the intermediary term type, resultant terms are ranked according to 
the highest co-occurring article count with the query term. One or more intermediary terms can 
be selected to complete the path search, and the final connection can either set as the MeSH term 
type or subtype. The resultant terms are again ranked by highest co-occurring article count with 
the intermediary terms. Once the path search has been completed, the user can access the articles 
associated with the final term via the PMID and can download the two previously described CSV 
files.    
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A 
B 
Figure 4.4. (A) Schema of the Path Search Module. The first query term, QT
1, is the input.  Next, 
a second layer of query terms (QT
2) that co-occur with QT
1 are selected. The number of terms in 
the second query layer can range from one (QT
2
1) to all associated terms (QT
2
n). Next, any category 
of MeSH term that co-occurs with QT
2 are returned. Solid lines indicate actual text-based co-
occurrences, while dashed lines indicate proposed connections. It should be noted that Q terms can 
be a combination A, B, or C terms. (B) Path Search Module Output. The first query term, 
“Kinase”, is the input. Co-occurring intermediary C terms, “Disease and Indications”, are returned. 
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Within this group, “Neoplasms” is selected as the second query layer, and the 9 802 chemical 
terms that co-occur with that term are returned.   
4.4.4 Find Articles 
In this module, articles indexed in PubMed can be searched for using specific MeSH 
terms. Additionally, this module will allow the user to inspect the total number of articles 
associated with this term. For example, if the term “Neoplasms” is queried, 36 1190 unique hits 
are returned with direct links to the respective articles.   
4.5.1 CASE STUDIES 
4.5.1.a Construction of a Clinical Outcome Pathway (COP) for a Drug-Disease Pair 
In order to demonstrate the utility of Chemotext, we describe its application for finding 
the accurate solution of the recent National Center for Advancing Translational Science 
(NCATS) Biomedical Data Translator Challenge 
(https://ncats.nih.gov/files/translator_FOA_2017.pdf).  The task of this challenge was to construct a 
clinical outcome pathway (COP) for the drug-disease pair imatinib-asthma.  It was stated that a 
clinical outcome pathway (COP) begins with (i) a molecule physically interacting with (ii) a 
biological target that affects (iii) a biological pathway relevant to (iv) a particular cell or tissue 
type that manifest as (v) a clinical phenotype and/or symptom which reflect (vi) a disease or 
condition. The challenge was to construct a COP for (i) imatinib that successfully reveals its (ii) 
biological target, (iii) the pathway affected by that target, (iv) the cell or tissue type, and (v) the 
manifested symptom germane to (vi) asthma in the form of relevant MeSH terms and associated 
article PMIDs for stages ii-v (Figure 4.5).   
 
 
118 
 
 
 
Figure 4.5. NCATS Biomedical Data Translator  
Challenge #5. The task was to successfully construct  
a COP connecting imatinib and asthma.  
Correct MeSH terms and associated article PMIDs 
had to be identified to solve the challenge. 
 
In the first step of the solution-seeking algorithm, query terms “Imatinib” (i) and 
“Asthma” (vi) were searched in the Find Shared Terms module. The list of full associations was 
filtered by “Proteins-Pathways-Intermediaries-Other”.  The MeSH term “Proto-Oncogene 
Proteins c-kit” was the fourth highest ranked shared term (two shared articles) selected as the 
potential biological target (ii) in the COP. The three more highly ranked terms, i.e., “Allergens”, 
“Stem Cell Factor”, and “Ovalbumin”, were deemed too broad or generic to be viable solutions. 
The two articles and their associated PMIDs related to “Proto-Oncogene Proteins c-kit” were 
then directly accessed through the Chemotext Web server. Both articles, upon visual inspection, 
confirmed the relevance of this DTD triangle. One article (PMID: 19722748)141, i.e., “Presence 
of c-KIT-positive mast cells in obliterative bronchiolitis from diverse causes”, was successfully 
chosen as the solution to stage (ii) of the COP, as later confirmed by the NCATS Challenge 
system.   
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To identify the biological pathway affected (iii) in this COP, query terms “Imatinib” (i) 
and “Proto-Oncogene Proteins c-kit” (ii) were searched in the Find Shared Terms module in the 
second step of the solution algorithm. The list of full associations was filtered by “Proteins-
Pathways-Intermediaries-Other”. The MeSH terms and associated article counts were 
downloaded from Chemotext. Next, query terms “Proto-Oncogene Proteins c-kit” (ii) and 
“Asthma” (vi) were searched in the Find Shared Terms module and the same succeeding steps as 
above were performed. The intersection of the two lists, i.e., (i-ii) and (ii-vi) was obtained, and 
MeSH terms were sorted according to article count ranks (Table S5). The MeSH term 
“Phosphatidylinositol 3-Kinases” was one of the most highly ranked shared terms (22nd out of 
928 terms). More highly ranked terms, such as “Biomarkers” and “Neoplasm Proteins”, were not 
selected because they were not relevant to the “Pathway” portion of this COP. Articles and their 
associated PMIDs related to “Phosphatidylinositol 3-Kinases” were then directly accessed 
through the Chemotext Web server. One article (PMID: 17546049)142, i.e., “KIT oncogenic 
signaling mechanisms in imatinib-resistant gastrointestinal stromal tumor: PI3-kinase/AKT is a 
crucial survival pathway”, was chosen as the successful solution to stage (iii) of the COP.   
In order to identify the cell or tissue type (iv) involved in this COP, “Imatinib” (i) and 
“Asthma” (vi) were again searched in the Find Shared Terms module.  Co-occurring terms were 
then filtered by “Cells”. This resulted in the correct identification of “Mast Cells” (PMID: 
16483568)143. Likewise, for the manifested symptom (v), the drug and the disease were queried 
in the Find Shared Terms module, and resultant connections were filtered by “Diseases and 
Indications”. The top co-occurring term was “Bronchial Hyperreactivity” (PMID: 24112389)144.  
Both the terms were later confirmed by the NCATS Challenge system as steps in the COP.    
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The full Imatinib-Asthma COP, as revealed by Chemotext and confirmed by the Challenge 
system, was:  Imatinib (i) → Proto-Oncogene Proteins c-kit (ii) → Phosphatidylinositol 3-
Kinases (iii) → Mast Cells (iv) → Bronchial Hyperreactivity (v) → Asthma (iv).   
It should be emphasized that expert-based knowledge curation, in conjunction with the 
results of Chemotext, was key for the successful identification of terms and articles.  For 
instance, in the first step of the solution algorithm, “Proto-Oncogene Proteins c-kit” was the 
correct target, but there were three more highly ranked terms, i.e., “Allergens”, “Stem Cell 
Factor”, and “Ovalbumin”. These terms were deemed too broad or generic to be viable solutions 
to this stage (ii) of the COP.  Likewise, in the second step, “Phosphatidylinositol 3-Kinases” 
ranked 22nd out of 928 terms. More highly ranked terms, such as “Biomarkers” and “Neoplasm 
Proteins”, however, were not biologically relevant (not related to “Pathway”) for this COP and 
thus not investigated.  This observation obligates that additional scoring functions - besides of 
article counts - should be considered to elucidate meaningful relationships. 
Last, it should be noted that this COP may have many alternative plausible solutions that have 
not been investigated herein; we have described a single validated test case merely to illustrate 
Chemotext’s capabilities.    
4.5.2.b Drug Repurposing for Human Cytomegalovirus 
In April 2017, Arend et. al. published a study that identified kinases upregulated during 
human cytomegalovirus (HCMV) infection and sought to repurpose kinase inhibitors as novel 
HCMV antivirals145.  Chiefly, Arend et al. found that the experimental kinase inhibitors 
OTSSP167 and dinaciclib were nanomolar inhibitors of HCMV.  Since this study was just 
recently published in 2017, this article has not yet been indexed with MeSH terms and is not yet 
part of the Chemotext database. This study, thus, can be used to test the ability Chemotext to 
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identify these compounds as HCMV inhibitors solely through text-based relationships, as it 
represents an A-B-C paradigm.  
Using the Path Search module, the relevant MeSH A-term “Cytomegalovirus” was 
queried, and “Proteins-Pathways-Intermediaries-Other” was selected as the intermediary term 
type. As a result, 3148 unique A-B connections were returned; however, since the study of 
interest focused only on kinase targets, the 101 B-terms associated with kinases were selected for 
further querying. These 101 kinase-associated B-terms range from broad terms, such as “Protein 
Kinases”, to more specialized terms, such as “ZAP-70 Protein-Tyrosine Kinase”. These B-terms 
were then queried for “Chemical” terms to complete the A-B-C paradigm. 
Ultimately, 16232 unique chemicals, which includes experimental drugs, were associated with 
the “Cytomegalovirus-Kinase” connection. Among these, the MELK inhibitor OTSSP167 
(which is indexed as by its IUPAC name “1-(6-(3,5-dichloro-4-hydroxyphenyl)-4-((4-
((dimethylamino)methyl)cyclohexyl)amino)-1,5-naphthyridin-3-yl)ethanone”) and the CDK 
inhibitor dinaciclib were found to be associated with “Cytomegalovirus” as mediated through 
kinase B-terms, with 4 and 19 associated articles, respectively. Chemotext was, therefore, 
successful at identifying drug repurposing candidates for the treatment of HCMV infection.   
It is important to note that these experimental drugs had not yet co-occurred in the same 
articles as “Cytomegalovirus;” thus, this the A-C relationship can only be established via the A-
B-C paradigm implemented in Chemotext.  
4.6 CONCLUSIONS 
We have developed the Chemotext Web server to facilitate the identification of existing 
drug-target-disease (DTD) relationships and to generate hypotheses about novel relationships by 
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mining of PubMed in the form of MeSH terms via four modules: Connected Terms, Find Shared 
Terms, Path Search, and Find Articles. In the Connected Terms module (Figure 4.2A), the user 
can query any type of MeSH terms, i.e., an A, B, or C term, and retrieve all MeSH terms that co-
occur in the same articles as the query term. This module provides an overview of all text-based 
associations and makes connections between terms.  In the Find Share Terms module (Figure 
4.3A), two query terms are input, and co-occurring terms that are shared between the queries are 
returned. For instance, in this module the shared targets between two diseases or between a drug 
and disease can be identified. In the Path Search module (Figure 4.4A), full A-B-C connections 
can be established through intermediary MeSH terms. We provided an example of using 
Chemotext to generate drug repurposing candidates. Last, a focused search of PubMed via 
MeSH term keywords can be performed using the Find Articles module.  
The Chemotext Web server was originally conceived of and developed as a text-mining 
tool for inferring new drug-disease associations132,146, i.e., drug repurposing; however, 
Chemotext can be used to establish DTD triangles or to mine any type of text-based relationships 
between biomedical terms or concepts. For example, Chemotext could be used to establish 
protein-protein interaction networks through co-occurring B-terms or to uncover correlations in 
disease progression through co-occurring C-terms. The potential number and types of 
relationships that can be generated with Chemotext are myriad and not limited to the A-B-C 
paradigm described herein.  Indeed, in 2016, Alves et. al.147 used Chemotext outside of this 
paradigm to confirm the toxic effects of chemicals predicted as human skin sensitizers in a 
virtual screening campaign.  
In spite of its obvious advantages, Chemotext in its current form has several limitations 
that must be addressed. First, the deposition of articles into PubMed is ever-growing. As per data 
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availability in MBR, the database of terms that underlies Chemotext, must be updated regularly 
to capture these articles, and new literature-based connections between terms have to be 
generated. Additionally, from a functional aspect, relationships derived by Chemotext are limited 
to MeSH terms indexed in the abstracts of articles. Future implementations will seek to mine full 
articles, although this form of text-mining is orders of magnitude more difficult. In the same 
vein, Chemotext currently does not support natural language processing and provides no 
inference about the nature of the relationship between the terms (agonism vs. antagonism, cause 
vs. effect, mode of action vs. side effect, etc.). This may lead to a number of false positive hits 
that are not directly related to the desired effect. From a technical perspective, chemicals can be 
queried by multiple synonyms, i.e., aspirin vs. acetylsalicylic acid vs. dispril. The “Click to 
Include Subterms” feature of Chemotext ensures that all terms associated with a chemical will be 
investigated.  On the other hand, chemicals will be returned only by the main MeSH term, i.e., 
aspirin. The user must be aware that the resultant chemical may be indexed by an unfamiliar 
construction, such as its IUPAC or generic name. Presently, the onus is placed on the user to then 
identify and investigate the chemical(s) of interest by the corresponding MeSH term. To address 
these issues and to improve the scope and functionality of Chemotext, regular updates and 
improvements are underway, such as improving its functionality on additional web browsers like 
Safari and Firefox and resolving chemical names.  
The Chemotext Web server is freely-available at http://Chemotext.mml.unc.edu/index.html 
(currently fully operational via Google Chrome only).  A user-friendly tutorial is also available at 
the site: http://chemotext.mml.unc.edu/ChemotextAppNote_Tutorial_v3.docx 
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4.7 ASSOCIATED CONTENT 
Supporting Information. Results of Chemotext queries described in the manuscript and 
other Chemotext related information (Tables S1-S6) for Chapter 4 are provided as Supporting 
Information at https://scapuzzi.web.unc.edu/free-downloads/. 
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